Rapid	O
Ca2+-mediated	O
activation	O
of	O
Rap1	B-protein
in	O
human	B-cell_type
platelets	I-cell_type
.	O

Rap1	B-protein
is	O
a	O
small	O
,	O
Ras-like	B-protein
GTPase	I-protein
whose	O
function	O
and	O
regulation	O
are	O
still	O
largely	O
unknown	O
.	O

We	O
have	O
developed	O
a	O
novel	O
assay	O
to	O
monitor	O
the	O
active	O
,	O
GTP-bound	B-protein
form	I-protein
of	O
Rap1	B-protein
based	O
on	O
the	O
differential	O
affinity	O
of	O
Rap1GTP	B-protein
and	O
Rap1GDP	B-protein
for	O
the	O
Rap	B-protein
binding	I-protein
domain	I-protein
of	O
RalGDS	B-protein
(	O
RBD	B-protein
)	O
.	O

Stimulation	O
of	O
blood	B-cell_type
platelets	I-cell_type
with	O
alpha-thrombin	B-protein
or	O
other	O
platelet	O
activators	O
caused	O
a	O
rapid	O
and	O
strong	O
induction	O
of	O
Rap1	B-protein
that	O
associated	O
with	O
RBD	B-protein
in	O
vitro	O
.	O

Binding	O
to	O
RBD	B-protein
increased	O
from	O
undetectable	O
levels	O
in	O
resting	B-cell_type
platelets	I-cell_type
to	O
>	O
50	O
%	O
of	O
total	O
Rap1	B-protein
within	O
30	O
s	O
after	O
stimulation	O
.	O

An	O
increase	O
in	O
the	O
intracellular	O
Ca2+	O
concentration	O
is	O
both	O
necessary	O
and	O
sufficient	O
for	O
Rap1	B-protein
activation	O
since	O
it	O
was	O
induced	O
by	O
agents	O
that	O
increase	O
intracellular	O
Ca2+	O
and	O
inhibited	O
by	O
a	O
Ca2+-chelating	O
agent	O
.	O

Neither	O
inhibition	O
of	O
translocation	O
of	O
Rap1	B-protein
to	O
the	O
cytoskeleton	O
nor	O
inhibition	O
of	O
platelet	O
aggregation	O
affected	O
thrombin	B-protein
-induced	O
activation	O
of	O
Rap1	B-protein
.	O

In	O
contrast	O
,	O
prostaglandin	O
I2	O
(	O
PGI2	O
)	O
,	O
a	O
strong	O
negative	O
regulator	O
of	O
platelet	B-cell_type
function	O
,	O
inhibited	O
agonist-induced	O
as	O
well	O
as	O
Ca2+-induced	O
activation	O
of	O
Rap1	B-protein
.	O

From	O
our	O
results	O
,	O
we	O
conclude	O
that	O
Rap1	B-protein
activation	O
in	O
platelets	B-cell_type
is	O
an	O
important	O
common	O
event	O
in	O
early	O
agonist-induced	O
signalling	O
,	O
and	O
that	O
this	O
activation	O
is	O
mediated	O
by	O
an	O
increased	O
intracellular	O
Ca2+	O
concentration	O

The	NULL
EMBO	NULL
Journal	NULL
Vol.16	NULL
No.2	NULL
pp.252-259	NULL
,	NULL
1997	NULL
Rapid	NULL
Ca**+-mediated	NULL
activation	NULL
of	NULL
Rap1	NULL
in	NULL
human	NULL
platelets	NULL
Barbara	NULL
Franke	NULL
,	NULL
Jan-Willem	NULL
N.Akkerman	NULL
and	NULL
Johannes	NULL
Laboratory	NULL
for	NULL
Physiological	NULL
Chemistry	NULL
,	NULL
Utrecht	NULL
University	NULL
,	NULL
PO	NULL
Box	NULL
80042	NULL
,	NULL
3508	NULL
TA	NULL
Utrecht	NULL
and	NULL
*Department	NULL
of	NULL
Haematology	NULL
,	NULL
University	NULL
Hospital	NULL
Utrecht	NULL
,	NULL
PO	NULL
Box	NULL
85500	NULL
,	NULL
3508	NULL
GA	NULL
Utrecht	NULL
,	NULL
The	NULL
Netherlands	NULL
``	NULL
Corresponding	NULL
author	NULL
Rapl	NULL
is	NULL
a	NULL
small	NULL
,	NULL
Ras-like	NULL
GTPase	NULL
whose	NULL
function	NULL
and	NULL
regulation	NULL
are	NULL
still	NULL
largely	NULL
unknown	NULL
.	NULL

We	NULL
have	NULL
developed	NULL
a	NULL
novel	NULL
assay	NULL
to	NULL
monitor	NULL
the	NULL
active	NULL
,	NULL
GTP-bound	NULL
form	NULL
of	NULL
Rap1l	NULL
based	NULL
on	NULL
the	NULL
differential	NULL
affinity	NULL
of	NULL
Rap1lGTP	NULL
and	NULL
RaplGDP	NULL
for	NULL
the	NULL
Rap	NULL
binding	NULL
domain	NULL
of	NULL
RalGDS	NULL
(	NULL
RBD	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
blood	NULL
platelets	NULL
with	NULL
or	NULL
other	NULL
platelet	NULL
activators	NULL
caused	NULL
a	NULL
rapid	NULL
and	NULL
strong	NULL
induction	NULL
of	NULL
Rapl	NULL
that	NULL
associated	NULL
with	NULL
RBD	NULL
ir	NULL
vitro	NULL
.	NULL

Binding	NULL
to	NULL
RBD	NULL
increased	NULL
from	NULL
undetectable	NULL
levels	NULL
in	NULL
resting	NULL
platelets	NULL
to	NULL
>	NULL
50	NULL
%	NULL
of	NULL
total	NULL
Rapl	NULL
within	NULL
30	NULL
s	NULL
after	NULL
stimulation	NULL
.	NULL

An	NULL
increase	NULL
in	NULL
the	NULL
intracellular	NULL
Ca**	NULL
concentration	NULL
is	NULL
both	NULL
necessary	NULL
and	NULL
sufficient	NULL
for	NULL
Rapl	NULL
activation	NULL
since	NULL
it	NULL
was	NULL
induced	NULL
by	NULL
agents	NULL
that	NULL
increase	NULL
intracellular	NULL
Ca	NULL
*	NULL
and	NULL
inhibited	NULL
by	NULL
a	NULL
Ca**-chelating	NULL
agent	NULL
.	NULL

Neither	NULL
inhibition	NULL
of	NULL
translocation	NULL
of	NULL
Rap1	NULL
to	NULL
the	NULL
cytoskeleton	NULL
nor	NULL
inhibition	NULL
of	NULL
platelet	NULL
aggregation	NULL
affected	NULL
thrombin-induced	NULL
activation	NULL
of	NULL
Rap1	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
prostaglandin	NULL
I	NULL
;	NULL
,	NULL
(	NULL
PGI	NULL
)	NULL
,	NULL
a	NULL
strong	NULL
negative	NULL
regulator	NULL
of	NULL
platelet	NULL
function	NULL
,	NULL
inhibited	NULL
agonist-induced	NULL
as	NULL
well	NULL
as	NULL
-induced	NULL
activation	NULL
of	NULL
Rapl	NULL
.	NULL

From	NULL
our	NULL
results	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
Rapl	NULL
activation	NULL
in	NULL
platelets	NULL
is	NULL
an	NULL
important	NULL
common	NULL
event	NULL
in	NULL
early	NULL
agonist-induced	NULL
signalling	NULL
,	NULL
and	NULL
that	NULL
this	NULL
activation	NULL
is	NULL
mediated	NULL
by	NULL
an	NULL
increased	NULL
intracellular	NULL
Ca+*	NULL
concentration	NULL
.	NULL

Keywords	NULL
:	NULL
calcium/GTPase/platelet/Rap1/thrombin	NULL
Introduction	NULL
Rap1A	NULL
and	NULL
Rap1lB	NULL
are	NULL
two	NULL
members	NULL
of	NULL
the	NULL
Ras	NULL
family	NULL
of	NULL
small	NULL
GTPases	NULL
.	NULL

RaplA	NULL
was	NULL
first	NULL
identified	NULL
both	NULL
by	NULL
its	NULL
homology	NULL
to	NULL
Ras	NULL
and	NULL
as	NULL
the	NULL
product	NULL
of	NULL
a	NULL
cDNA	NULL
that	NULL
induces	NULL
flat	NULL
revertants	NULL
of	NULL
K-ras-transformed	NULL
cells	NULL
(	NULL
Krey-1	NULL
)	NULL
.	NULL

Rap1B	NULL
is	NULL
a	NULL
very	NULL
close	NULL
relative	NULL
of	NULL
Rap1	NULL
A	NULL
,	NULL
differing	NULL
in	NULL
only	NULL
nine	NULL
amino	NULL
acids	NULL
predominantly	NULL
in	NULL
the	NULL
C-terminal	NULL
part	NULL
of	NULL
the	NULL
protein	NULL
(	NULL
Noda	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

The	NULL
functional	NULL
difference	NULL
between	NULL
the	NULL
two	NULL
proteins	NULL
is	NULL
unclear	NULL
and	NULL
in	NULL
most	NULL
studies	NULL
no	NULL
discrimination	NULL
between	NULL
the	NULL
two	NULL
has	NULL
been	NULL
made	NULL
.	NULL

Various	NULL
functions	NULL
of	NULL
Rapl	NULL
have	NULL
been	NULL
described	NULL
,	NULL
some	NULL
of	NULL
which	NULL
are	NULL
related	NULL
to	NULL
the	NULL
ability	NULL
of	NULL
Rap1	NULL
to	NULL
counteract	NULL
the	NULL
function	NULL
of	NULL
Ras	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
introduction	NULL
of	NULL
the	NULL
active	NULL
,	NULL
GTP-bound	NULL
form	NULL
of	NULL
Rapl1	NULL
into	NULL
fibroblasts	NULL
inhibits	NULL
Ras-mediated	NULL
activation	NULL
of	NULL
MAP	NULL
kinase	NULL
(	NULL
Cook	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
constitutively	NULL
active	NULL
Rapl	NULL
can	NULL
inhibit	NULL
Ras-mediated	NULL
induction	NULL
of	NULL
germinal	NULL
vesicle	NULL
breakdown	NULL
in	NULL
Xenopus	NULL
oocytes	NULL
252	NULL
(	NULL
Campa	NULL
et	NULL
al.,1991	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
Rapl	NULL
binds	NULL
regulators	NULL
(	NULL
p120®S4	NULL
``	NULL
;	NULL
Frech	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Hata	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
and	NULL
effectors	NULL
(	NULL
Rafl	NULL
,	NULL
RalGDS	NULL
;	NULL
Spaargaren	NULL
and	NULL
Bischoff	NULL
,	NULL
1994	NULL
;	NULL
Nassar	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Wittinghofer	NULL
and	NULL
Herrmann	NULL
,	NULL
1995	NULL
)	NULL
of	NULL
Ras	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
Ras	NULL
function	NULL
is	NULL
due	NULL
to	NULL
sequestration	NULL
of	NULL
Ras	NULL
effectors	NULL
by	NULL
Rapl	NULL
.	NULL

Interestingly	NULL
,	NULL
cAMP	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
Ras	NULL
signalling	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
(	NULL
Burgering	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Cook	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Wu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
induce	NULL
the	NULL
activation	NULL
of	NULL
exogenously	NULL
expressed	NULL
epitope-tagged	NULL
Rapl	NULL
in	NULL
a	NULL
Ras-transformed	NULL
fibroblast	NULL
(	NULL
Altschuler	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

However	NULL
,	NULL
not	NULL
all	NULL
effects	NULL
of	NULL
Rapl	NULL
point	NULL
to	NULL
an	NULL
inhibition	NULL
of	NULL
Ras	NULL
signalling	NULL
and	NULL
indicate	NULL
that	NULL
Rapl	NULL
has	NULL
a	NULL
separate	NULL
function	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
in	NULL
Swiss	NULL
3T3	NULL
fibroblasts	NULL
,	NULL
constitutively	NULL
active	NULL
Rapl	NULL
induces	NULL
DNA	NULL
synthesis	NULL
(	NULL
Yoshida	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

In	NULL
neutrophils	NULL
,	NULL
Rapl	NULL
is	NULL
found	NULL
in	NULL
association	NULL
with	NULL
the	NULL
NADPH	NULL
oxidase	NULL
system	NULL
(	NULL
Quinn	NULL
et	NULL
aZ	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
,	NULL
and	NULL
introduction	NULL
of	NULL
Rap1	NULL
into	NULL
neutrophil-like	NULL
HL60	NULL
cells	NULL
results	NULL
in	NULL
a	NULL
stimulation	NULL
of	NULL
this	NULL
oxidase	NULL
(	NULL
Gabig	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
in	NULL
blood	NULL
platelets	NULL
,	NULL
Rapl	NULL
may	NULL
play	NULL
an	NULL
important	NULL
role	NULL
,	NULL
since	NULL
Rap1	NULL
,	NULL
in	NULL
particular	NULL
Rap1B	NULL
,	NULL
is	NULL
highly	NULL
expressed	NULL
(	NULL
Torti	NULL
and	NULL
Lapetina	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

Platelets	NULL
are	NULL
anuclear	NULL
cell	NULL
fragments	NULL
that	NULL
adhere	NULL
to	NULL
sites	NULL
of	NULL
injury	NULL
in	NULL
a	NULL
blood	NULL
vessel	NULL
and	NULL
aggregate	NULL
to	NULL
stop	NULL
bleeding	NULL
.	NULL

Adhesion	NULL
and	NULL
aggregation	NULL
are	NULL
accompanied	NULL
by	NULL
a	NULL
profound	NULL
change	NULL
in	NULL
the	NULL
morphology	NULL
of	NULL
platelets	NULL
due	NULL
to	NULL
remodelling	NULL
of	NULL
the	NULL
actin-based	NULL
cytoskeleton	NULL
(	NULL
Hartwig	NULL
,	NULL
1992	NULL
;	NULL
Fox	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

Thrombin	NULL
is	NULL
the	NULL
most	NULL
potent	NULL
stimulator	NULL
of	NULL
platelets	NULL
,	NULL
but	NULL
a	NULL
large	NULL
number	NULL
of	NULL
other	NULL
activators	NULL
has	NULL
been	NULL
described	NULL
(	NULL
Kroll	NULL
and	NULL
Schafer	NULL
,	NULL
1989	NULL
;	NULL
Siess	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

When	NULL
platelets	NULL
are	NULL
activated	NULL
,	NULL
Rap1	NULL
is	NULL
translocated	NULL
to	NULL
the	NULL
platelet	NULL
cytoskeleton	NULL
(	NULL
Fischer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

This	NULL
translocation	NULL
is	NULL
a	NULL
relatively	NULL
slow	NULL
process	NULL
that	NULL
depends	NULL
on	NULL
aggregation	NULL
of	NULL
platelets	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
Rapl	NULL
associates	NULL
with	NULL
p120®*°*	NULL
``	NULL
and	NULL
PLCYy	NULL
;	NULL
after	NULL
platelet	NULL
stimulation	NULL
(	NULL
Torti	NULL
and	NULL
Lapetina	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
prostaglandin	NULL
I	NULL
;	NULL
(	NULL
PGI	NULL
;	NULL
)	NULL
,	NULL
a	NULL
strong	NULL
negative	NULL
regulator	NULL
of	NULL
platelet	NULL
function	NULL
,	NULL
affects	NULL
Rapl	NULL
by	NULL
inducing	NULL
the	NULL
phosphorylation	NULL
of	NULL
a	NULL
serine	NULL
residue	NULL
at	NULL
the	NULL
C-terminal	NULL
end	NULL
of	NULL
Rapl	NULL
(	NULL
Kawata	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Siess	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

This	NULL
phosphorylation	NULL
induces	NULL
a	NULL
translocation	NULL
of	NULL
Rapl	NULL
from	NULL
the	NULL
plasma	NULL
membrane	NULL
to	NULL
the	NULL
cytosol	NULL
(	NULL
Lapetina	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Despite	NULL
all	NULL
these	NULL
results	NULL
,	NULL
it	NULL
is	NULL
still	NULL
unclear	NULL
what	NULL
the	NULL
function	NULL
of	NULL
Rapl	NULL
is	NULL
and	NULL
in	NULL
which	NULL
signal	NULL
transduction	NULL
pathway	NULL
Rapl	NULL
is	NULL
involved	NULL
.	NULL

This	NULL
is	NULL
partly	NULL
due	NULL
to	NULL
the	NULL
lack	NULL
of	NULL
information	NULL
on	NULL
signals	NULL
that	NULL
may	NULL
activate	NULL
endogenous	NULL
Rapl	NULL
,	NULL
i.e	NULL
.	NULL

induce	NULL
the	NULL
conversion	NULL
of	NULL
the	NULL
inactive	NULL
GDP-bound	NULL
form	NULL
of	NULL
the	NULL
protein	NULL
to	NULL
the	NULL
active	NULL
GTP-bound	NULL
form	NULL
.	NULL

Unfortunately	NULL
,	NULL
no	NULL
antibodies	NULL
are	NULL
available	NULL
that	NULL
can	NULL
immunoprecipitate	NULL
Rapl	NULL
to	NULL
measure	NULL
the	NULL
ratio	NULL
of	NULL
GTP	NULL
:	NULL
GDP	NULL
bound	NULL
to	NULL
Rap1	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
have	NULL
developed	NULL
an	NULL
altern-ative	NULL
,	NULL
indirect	NULL
assay	NULL
to	NULL
measure	NULL
Rapl	NULL
activation	NULL
.	NULL

This	NULL
assay	NULL
is	NULL
based	NULL
on	NULL
the	NULL
differential	NULL
affinity	NULL
of	NULL
Rap1GTP	NULL
versus	NULL
Rap1GDP	NULL
for	NULL
the	NULL
Rap	NULL
binding	NULL
domain	NULL
of	NULL
RalGDS	NULL
©	NULL
Oxford	NULL
University	NULL
Press	NULL
(	NULL
RBD	NULL
)	NULL
as	NULL
shown	NULL
by	NULL
Wittinghofer	NULL
and	NULL
co-workers	NULL
(	NULL
Herrmann	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
:	NULL
whereas	NULL
the	NULL
Rap	NULL
binding	NULL
domain	NULL
of	NULL
RalGDS	NULL
binds	NULL
to	NULL
the	NULL
GTP-bound	NULL
form	NULL
of	NULL
Rapl	NULL
with	NULL
a	NULL
very	NULL
high	NULL
affinity	NULL
(	NULL
K	NULL
,	NULL
=10	NULL
nM	NULL
)	NULL
,	NULL
the	NULL
affinity	NULL
for	NULL
the	NULL
GDP-bound	NULL
form	NULL
is	NULL
undetectably	NULL
low	NULL
.	NULL

Here	NULL
we	NULL
report	NULL
that	NULL
in	NULL
platelets	NULL
(	NULL
-thrombin	NULL
stimulation	NULL
results	NULL
in	NULL
a	NULL
dramatic	NULL
increase	NULL
of	NULL
Rapl	NULL
which	NULL
can	NULL
associate	NULL
with	NULL
RBD	NULL
in	NULL
vitro	NULL
,	NULL
indicating	NULL
an	NULL
increase	NULL
of	NULL
Rapl	NULL
in	NULL
the	NULL
GTP-bound	NULL
state	NULL
.	NULL

We	NULL
have	NULL
investigated	NULL
this	NULL
activation	NULL
further	NULL
and	NULL
found	NULL
that	NULL
most	NULL
,	NULL
if	NULL
not	NULL
all	NULL
,	NULL
activators	NULL
of	NULL
platelet	NULL
function	NULL
activate	NULL
Rap1	NULL
,	NULL
whereas	NULL
the	NULL
negative	NULL
regulator	NULL
PGI	NULL
;	NULL
inhibits	NULL
Rapl	NULL
activation	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
show	NULL
that	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
intracellular	NULL
Ca*	NULL
``	NULL
+*	NULL
concentration	NULL
is	NULL
both	NULL
necessary	NULL
and	NULL
sufficient	NULL
to	NULL
activate	NULL
Rapl	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
show	NULL
that	NULL
Rapl	NULL
activation	NULL
occurs	NULL
independently	NULL
of	NULL
,	NULL
and	NULL
probably	NULL
prior	NULL
to	NULL
,	NULL
platelet	NULL
aggregation	NULL
and	NULL
the	NULL
association	NULL
of	NULL
Rapl	NULL
with	NULL
the	NULL
cytoskeleton	NULL
.	NULL

From	NULL
these	NULL
results	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
Rapl	NULL
is	NULL
activated	NULL
rapidly	NULL
and	NULL
strongly	NULL
by	NULL
Ca**-mediated	NULL
signalling	NULL
after	NULL
platelet	NULL
stimulation	NULL
,	NULL
suggesting	NULL
a	NULL
critical	NULL
role	NULL
for	NULL
Rapl	NULL
in	NULL
platelet	NULL
activation	NULL
.	NULL

Results	NULL
&	NULL
-Thrombin	NULL
induces	NULL
rapid	NULL
activation	NULL
of	NULL
Rap1	NULL
Freshly	NULL
isolated	NULL
human	NULL
platelets	NULL
were	NULL
stimulated	NULL
with	NULL
&	NULL
-thrombin	NULL
for	NULL
various	NULL
time	NULL
periods	NULL
and	NULL
lysed	NULL
.	NULL

Rapl	NULL
was	NULL
precipitated	NULL
with	NULL
the	NULL
polyhistidine-tagged	NULL
Rap	NULL
binding	NULL
domain	NULL
of	NULL
RalGDS	NULL
(	NULL
RBD	NULL
)	NULL
bound	NULL
to	NULL
nickel	NULL
beads	NULL
and	NULL
identified	NULL
by	NULL
Western	NULL
blotting	NULL
using	NULL
a	NULL
monoclonal	NULL
antibody	NULL
directed	NULL
against	NULL
Rap1	NULL
.	NULL

This	NULL
antibody	NULL
is	NULL
specific	NULL
for	NULL
Rapl	NULL
,	NULL
and	NULL
does	NULL
not	NULL
recognize	NULL
Ras	NULL
or	NULL
R-ras	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
rapid	NULL
and	NULL
strong	NULL
increase	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
Rapl	NULL
that	NULL
bound	NULL
to	NULL
RBD	NULL
in	NULL
vitro	NULL
was	NULL
observed	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

This	NULL
increase	NULL
was	NULL
visible	NULL
within	NULL
5	NULL
s	NULL
after	NULL
thrombin	NULL
addition	NULL
and	NULL
reached	NULL
its	NULL
maximum	NULL
level	NULL
at	NULL
~30	NULL
s.	NULL
At	NULL
this	NULL
latter	NULL
time	NULL
point	NULL
,	NULL
>	NULL
50	NULL
%	NULL
of	NULL
total	NULL
Rapl	NULL
could	NULL
be	NULL
precipitated	NULL
with	NULL
RBD	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

Since	NULL
RBD	NULL
associates	NULL
exclusively	NULL
with	NULL
the	NULL
GTP-bound	NULL
form	NULL
of	NULL
Rapl	NULL
in	NULL
vitro	NULL
,	NULL
with	NULL
no	NULL
detectable	NULL
affinity	NULL
for	NULL
the	NULL
GDP-bound	NULL
form	NULL
of	NULL
Rapl	NULL
(	NULL
Herrmann	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
induces	NULL
a	NULL
rapid	NULL
conversion	NULL
of	NULL
the	NULL
majority	NULL
of	NULL
Rapl	NULL
to	NULL
the	NULL
GTP-bound	NULL
,	NULL
active	NULL
state	NULL
.	NULL

Treatment	NULL
of	NULL
platelets	NULL
with	NULL
agonists	NULL
other	NULL
than	NULL
-thrombin	NULL
(	NULL
Benton	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
;	NULL
Kroll	NULL
and	NULL
Schafer	NULL
,	NULL
1989	NULL
;	NULL
Siess	NULL
,	NULL
1989	NULL
;	NULL
Inazu	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
also	NULL
caused	NULL
activation	NULL
of	NULL
Rapl1	NULL
;	NULL
the	NULL
thrombin	NULL
receptor-activating	NULL
peptide	NULL
(	NULL
TRAP	NULL
)	NULL
,	NULL
collagen	NULL
,	NULL
the	NULL
thromboxane	NULL
A	NULL
;	NULL
,	NULL
(	NULL
TxA	NULL
;	NULL
,	NULL
)	NULL
analogue	NULL
U46619	NULL
,	NULL
ADP	NULL
and	NULL
platelet-activating	NULL
factor	NULL
(	NULL
PAF	NULL
)	NULL
all	NULL
induced	NULL
rapid	NULL
and	NULL
strong	NULL
Rapl	NULL
activation	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

Wheat	NULL
germ	NULL
agglutinin	NULL
and	NULL
lysophosphatidic	NULL
acid	NULL
(	NULL
LPA	NULL
)	NULL
treatment	NULL
also	NULL
resulted	NULL
in	NULL
Rapl	NULL
activation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

From	NULL
these	NULL
results	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
Rapl	NULL
is	NULL
activated	NULL
rapidly	NULL
and	NULL
strongly	NULL
by	NULL
signalling	NULL
events	NULL
common	NULL
to	NULL
most	NULL
,	NULL
if	NULL
not	NULL
all	NULL
platelet	NULL
agonists	NULL
.	NULL

Rap1	NULL
activation	NULL
occurs	NULL
independently	NULL
of	NULL
secretion	NULL
and	NULL
platelet	NULL
aggregation	NULL
During	NULL
thrombin-induced	NULL
platelet	NULL
activation	NULL
,	NULL
TxA	NULL
,	NULL
and	NULL
ADP	NULL
are	NULL
released	NULL
by	NULL
platelets	NULL
.	NULL

Both	NULL
act	NULL
in	NULL
positive	NULL
feedback	NULL
loops	NULL
to	NULL
enhance	NULL
further	NULL
the	NULL
ongoing	NULL
platelet	NULL
activation	NULL
(	NULL
Kroll	NULL
and	NULL
Schafer	NULL
,	NULL
1989	NULL
;	NULL
Siess	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

As	NULL
TxA	NULL
,	NULL
and	NULL
ADP	NULL
induce	NULL
Rap1	NULL
activation	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
thrombin-induced	NULL
Rapl	NULL
activation	NULL
is	NULL
a	NULL
consequence	NULL
of	NULL
these	NULL
pro	NULL
Rap1	NULL
activation	NULL
in	NULL
platelets	NULL
~	NULL
.	NULL

-—_	NULL
‘	NULL
4	NULL
Rap	NULL
0	NULL
1	NULL
5	NULL
10	NULL
20	NULL
30	NULL
60	NULL
time	NULL
(	NULL
sec	NULL
)	NULL
B	NULL
-	NULL
__+	NULL
RBD	NULL
e	NULL
4-	NULL
Rap1	NULL
Fig	NULL
.	NULL

1.	NULL
stimulation	NULL
of	NULL
blood	NULL
platelets	NULL
results	NULL
in	NULL
increased	NULL
binding	NULL
of	NULL
Rapl	NULL
to	NULL
RBD	NULL
in	NULL
vitro	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Platelets	NULL
were	NULL
stimulated	NULL
with	NULL
0.25	NULL
U/ml	NULL
-thrombin	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
periods	NULL
and	NULL
lysed	NULL
.	NULL

Rapl	NULL
was	NULL
precipitated	NULL
with	NULL
his-tagged	NULL
RBD	NULL
bound	NULL
to	NULL
Ni**-NTA-agarose	NULL
beads	NULL
,	NULL
and	NULL
identified	NULL
with	NULL
a	NULL
monoclonal	NULL
antibody	NULL
directed	NULL
against	NULL
Rapl	NULL
after	NULL
SDS-PAGE	NULL
and	NULL
Western	NULL
blotting	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Platelet	NULL
lysate	NULL
was	NULL
incubated	NULL
with	NULL
either	NULL
Ni	NULL
*-NTA-agarose	NULL
beads	NULL
(	NULL
-	NULL
)	NULL
or	NULL
his-tagged	NULL
RBD	NULL
bound	NULL
to	NULL
beads	NULL
(	NULL
+	NULL
)	NULL
.	NULL

After	NULL
removal	NULL
of	NULL
the	NULL
beads	NULL
,	NULL
the	NULL
supernatant	NULL
was	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
and	NULL
Rapl	NULL
was	NULL
detected	NULL
by	NULL
immunoblotting	NULL
with	NULL
a	NULL
Rapl-specific	NULL
monoclonal	NULL
antibody	NULL
.	NULL

$	NULL
&	NULL
8	NULL
-£	NULL
6	NULL
J	NULL
£	NULL
``	NULL
P	NULL
C	NULL
&	NULL
-	NULL
$	NULL
>	NULL
W	NULL
S	NULL
3	NULL
&	NULL
&	NULL
«	NULL
Q	NULL
?	NULL

&	NULL
``	NULL
”	NULL
83	NULL
.	NULL

&	NULL
3	NULL
v9	NULL
q	NULL
3	NULL
103	NULL
G1	NULL
3	NULL
1	NULL
3	NULL
1	NULL
3	NULL
4	NULL
3	NULL
G4	NULL
3	NULL
time	NULL
(	NULL
min	NULL
)	NULL
«	NULL
-a	NULL
dan	NULL
--	NULL
-*	NULL
--	NULL
_-—-—¢	NULL
--	NULL
-	NULL
``	NULL
4-	NULL
Rap1	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Rapl	NULL
activation	NULL
is	NULL
induced	NULL
by	NULL
different	NULL
platelet	NULL
agonists	NULL
.	NULL

Platelets	NULL
were	NULL
stimulated	NULL
for	NULL
1	NULL
and	NULL
3	NULL
min	NULL
with	NULL
(	NULL
0.1	NULL
U/ml	NULL
)	NULL
,	NULL
TRAP	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
,	NULL
collagen	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
,	NULL
the	NULL
thromboxane	NULL
A	NULL
;	NULL
analogue	NULL
U46619	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
,	NULL
ADP	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
and	NULL
PAF	NULL
(	NULL
200	NULL
nM	NULL
)	NULL
.	NULL

Resting	NULL
platelets	NULL
were	NULL
treated	NULL
with	NULL
buffer	NULL
for	NULL
3	NULL
min	NULL
.	NULL

Rapl	NULL
was	NULL
isolated	NULL
and	NULL
identified	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Figure	NULL
1.	NULL
cesses	NULL
.	NULL

Treatment	NULL
of	NULL
platelets	NULL
with	NULL
indomethacin	NULL
inhibits	NULL
TxA	NULL
,	NULL
formation	NULL
(	NULL
Shen	NULL
and	NULL
Winter	NULL
,	NULL
1977	NULL
)	NULL
;	NULL
addition	NULL
of	NULL
phosphoenolpyruvate	NULL
and	NULL
pyruvate	NULL
kinase	NULL
(	NULL
PEP	NULL
:	NULL
PK	NULL
)	NULL
scavenges	NULL
ADP	NULL
,	NULL
thus	NULL
inhibiting	NULL
ADP	NULL
signalling	NULL
(	NULL
Ammit	NULL
and	NULL
O'Neill	NULL
,	NULL
1991	NULL
;	NULL
Van	NULL
Willigen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
both	NULL
inhibitors	NULL
together	NULL
,	NULL
at	NULL
concentrations	NULL
causing	NULL
complete	NULL
inhibition	NULL
of	NULL
both	NULL
pathways	NULL
,	NULL
resulted	NULL
in	NULL
only	NULL
a	NULL
partial	NULL
inhibition	NULL
of	NULL
Rapl	NULL
activation	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

From	NULL
these	NULL
results	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
although	NULL
both	NULL
TxA	NULL
,	NULL
and	NULL
ADP	NULL
do	NULL
contribute	NULL
to	NULL
thrombin-induced	NULL
activation	NULL
of	NULL
Rap1	NULL
,	NULL
they	NULL
are	NULL
not	NULL
essential	NULL
for	NULL
thrombin	NULL
to	NULL
induce	NULL
Rapl	NULL
.	NULL

Previously	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
Rapl	NULL
translocates	NULL
to	NULL
the	NULL
platelet	NULL
cytoskeleton	NULL
in	NULL
a	NULL
mainly	NULL
aggregation-dependent	NULL
manner	NULL
(	NULL
Fischer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
investigated	NULL
the	NULL
effects	NULL
of	NULL
disruption	NULL
of	NULL
the	NULL
cytoskeleton	NULL
and	NULL
inhibition	NULL
of	NULL
platelet	NULL
aggregation	NULL
on	NULL
thrombin-induced	NULL
Rapl	NULL
activ-	NULL
253	NULL
B.Franke	NULL
,	NULL
J.-W.N.Akkerman	NULL
and	NULL
J.L.Bos	NULL
+	NULL
inhibitors	NULL
-	NULL
inhibitors	NULL
60	NULL
30	NULL
10	NULL
5	NULL
1	NULL
0	NULL
1	NULL
5	NULL
10	NULL
30	NULL
60	NULL
time	NULL
(	NULL
sec	NULL
)	NULL
*t	NULL
=~	NULL
sume	NULL
—-	NULL
‘	NULL
-	NULL
’	NULL
‘	NULL
_	NULL
Rap1	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Rapl	NULL
activation	NULL
occurs	NULL
independently	NULL
of	NULL
both	NULL
TxA	NULL
;	NULL
formation	NULL
and	NULL
ADP	NULL
secretion	NULL
.	NULL

In	NULL
the	NULL
lanes	NULL
marked	NULL
'+	NULL
inhibitors	NULL
'	NULL
platelets	NULL
were	NULL
incubated	NULL
with	NULL
30	NULL
M	NULL
indomethacin	NULL
for	NULL
10	NULL
min	NULL
to	NULL
inhibit	NULL
TxA	NULL
;	NULL
formation	NULL
.	NULL

In	NULL
the	NULL
last	NULL
minute	NULL
,	NULL
the	NULL
ADP	NULL
scavenger	NULL
system	NULL
phosphoenolpyruvate	NULL
:	NULL
pyruvate	NULL
kinase	NULL
(	NULL
PEP	NULL
:	NULL
PK	NULL
)	NULL
was	NULL
added	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.28	NULL
mM	NULL
PEP	NULL
and	NULL
3	NULL
U/ml	NULL
PK	NULL
.	NULL

Subsequently	NULL
,	NULL
the	NULL
platelets	NULL
were	NULL
incubated	NULL
with	NULL
0.1	NULL
U/ml	NULL
¢-thrombin	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
periods	NULL
,	NULL
and	NULL
Rap1	NULL
was	NULL
isolated	NULL
and	NULL
detected	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Figure	NULL
1	NULL
.	NULL

Control	NULL
platelets	NULL
(	NULL
-	NULL
inhibitors	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
0.1	NULL
U/ml	NULL
only	NULL
.	NULL

ation	NULL
.	NULL

Treatment	NULL
of	NULL
platelets	NULL
with	NULL
cytochalasin	NULL
D	NULL
prevents	NULL
activation-dependent	NULL
actin	NULL
polymerization	NULL
and	NULL
remodelling	NULL
of	NULL
the	NULL
cytoskeleton	NULL
(	NULL
Dash	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

This	NULL
treatment	NULL
totally	NULL
prevented	NULL
the	NULL
translocation	NULL
of	NULL
Rapl	NULL
to	NULL
the	NULL
cytoskeleton	NULL
(	NULL
Figure	NULL
4A	NULL
)	NULL
.	NULL

Cytochalasin	NULL
D	NULL
,	NULL
however	NULL
,	NULL
did	NULL
not	NULL
affect	NULL
thrombin-induced	NULL
activation	NULL
of	NULL
Rapl	NULL
(	NULL
Figure	NULL
4B	NULL
)	NULL
,	NULL
showing	NULL
that	NULL
Rapl	NULL
activation	NULL
occurs	NULL
independently	NULL
of	NULL
translocation	NULL
to	NULL
the	NULL
cytoskeleton	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
platelets	NULL
that	NULL
were	NULL
not	NULL
allowed	NULL
to	NULL
aggregate	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
RGDS	NULL
peptide	NULL
,	NULL
which	NULL
blocks	NULL
integrin	NULL
function	NULL
(	NULL
Hynes	NULL
,	NULL
1992	NULL
;	NULL
Calvete	NULL
,	NULL
1994	NULL
)	NULL
,	NULL
Rapl	NULL
activation	NULL
was	NULL
not	NULL
impaired	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
inhibition	NULL
of	NULL
aggregation	NULL
by	NULL
not	NULL
stirring	NULL
the	NULL
platelet	NULL
suspension	NULL
did	NULL
not	NULL
affect	NULL
o-thrombin-induced	NULL
activation	NULL
of	NULL
Rapl	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

From	NULL
these	NULL
results	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
Rapl	NULL
activation	NULL
occurs	NULL
independently	NULL
of	NULL
Rapl	NULL
translocation	NULL
to	NULL
the	NULL
cytoskeleton	NULL
and	NULL
of	NULL
platelet	NULL
aggregation	NULL
.	NULL

Increase	NULL
in	NULL
intracellular	NULL
Ca	NULL
``	NULL
*	NULL
is	NULL
necessary	NULL
and	NULL
sufficient	NULL
for	NULL
Rap1	NULL
activation	NULL
One	NULL
of	NULL
the	NULL
signalling	NULL
events	NULL
shared	NULL
by	NULL
platelet	NULL
agonists	NULL
is	NULL
the	NULL
activation	NULL
of	NULL
phospholipase	NULL
C	NULL
(	NULL
PLC	NULL
)	NULL
,	NULL
which	NULL
releases	NULL
diacylglycerol	NULL
(	NULL
DAG	NULL
)	NULL
to	NULL
activate	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
,	NULL
and	NULL
inositol-1,4,5-triphosphate	NULL
(	NULL
InsP	NULL
;	NULL
)	NULL
to	NULL
mobilize	NULL
Ca**	NULL
from	NULL
intracellular	NULL
stores	NULL
(	NULL
Kroll	NULL
and	NULL
Schafer	NULL
,	NULL
1989	NULL
;	NULL
Siess	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

Figure	NULL
6A	NULL
demonstrates	NULL
that	NULL
inhibition	NULL
of	NULL
PLC	NULL
by	NULL
U73122	NULL
(	NULL
Okamoto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
strongly	NULL
reduced	NULL
thrombin-induced	NULL
activation	NULL
of	NULL
Rapl	NULL
,	NULL
suggesting	NULL
that	NULL
either	NULL
PKC	NULL
or	NULL
Ca**	NULL
is	NULL
an	NULL
important	NULL
factor	NULL
in	NULL
Rapl	NULL
regulation	NULL
.	NULL

We	NULL
therefore	NULL
tested	NULL
whether	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
intracellular	NULL
Ca**	NULL
concentration	NULL
is	NULL
important	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
Rap1	NULL
.	NULL

Inhibition	NULL
of	NULL
the	NULL
cytosolic	NULL
Ca**	NULL
increase	NULL
by	NULL
chelation	NULL
of	NULL
intracellular	NULL
Ca*+*	NULL
with	NULL
BAPTA-AM	NULL
(	NULL
Watson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
completely	NULL
blocked	NULL
activation	NULL
of	NULL
Rapl	NULL
by	NULL
a-thrombin	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
increasing	NULL
the	NULL
concentration	NULL
of	NULL
intracellular	NULL
Ca	NULL
``	NULL
+	NULL
with	NULL
ionomycin	NULL
(	NULL
Cavallini	NULL
and	NULL
Alexandre	NULL
,	NULL
1994	NULL
;	NULL
Doni	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
or	NULL
thapsigargin	NULL
(	NULL
Authi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Cavallini	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
strongly	NULL
activated	NULL
Rapl	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
an	NULL
increased	NULL
level	NULL
of	NULL
Ca**	NULL
is	NULL
both	NULL
necessary	NULL
and	NULL
sufficient	NULL
to	NULL
activate	NULL
Rap1	NULL
.	NULL

The	NULL
Ca**	NULL
effect	NULL
is	NULL
not	NULL
due	NULL
simply	NULL
to	NULL
Ca**-induced	NULL
production	NULL
and	NULL
release	NULL
254	NULL
A	NULL
0	NULL
0.5	NULL
1	NULL
2	NULL
time	NULL
(	NULL
min	NULL
)	NULL
4-	NULL
Rap	NULL
+	NULL
Cyto	NULL
D	NULL
«	NULL
--	NULL
»	NULL
<	NULL
-	NULL
Rapl	NULL
B	NULL
0	NULL
0.5	NULL
1	NULL
2	NULL
time	NULL
(	NULL
min	NULL
)	NULL
awp	NULL
am	NULL
»	NULL
aw	NULL
»	NULL
|	NULL
<	NULL
-	NULL
Rapl	NULL
+	NULL
Cyto	NULL
D	NULL
«	NULL
»	NULL
«	NULL
-as	NULL
«	NULL
--	NULL
-	NULL
|	NULL
4-Rapl	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Inhibition	NULL
of	NULL
actin	NULL
polymerization	NULL
prevents	NULL
Rapl	NULL
translocation	NULL
but	NULL
does	NULL
not	NULL
affect	NULL
thrombin-induced	NULL
activation	NULL
of	NULL
Rap1	NULL
.	NULL

Platelets	NULL
were	NULL
treated	NULL
with	NULL
cytochalasin	NULL
D	NULL
(	NULL
Cyto	NULL
D	NULL
,	NULL
5	NULL
ug/ml	NULL
!	NULL
)	NULL

(	NULL
top	NULL
)	NULL
or	NULL
DMSO	NULL
(	NULL
bottom	NULL
)	NULL
5	NULL
min	NULL
prior	NULL
to	NULL
stimulation	NULL
with	NULL
0.2	NULL
U/ml	NULL
¢-thrombin	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
periods	NULL
under	NULL
aggregating	NULL
conditions	NULL
(	NULL
stirring	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Cytoskeletal	NULL
proteins	NULL
were	NULL
isolated	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL

Amounts	NULL
of	NULL
protein	NULL
representing	NULL
3X	NULL
10	NULL
``	NULL
platelets	NULL
were	NULL
used	NULL
for	NULL
protein	NULL
immunoblot	NULL
analysis	NULL
with	NULL
a	NULL
monoclonal	NULL
antibody	NULL
directed	NULL
against	NULL
Rap1	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Rapl	NULL
was	NULL
precipitated	NULL
with	NULL
RBD	NULL
and	NULL
analysed	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
legend	NULL
of	NULL
Figure	NULL
1	NULL
.	NULL

The	NULL
band	NULL
present	NULL
above	NULL
Rapl	NULL
is	NULL
caused	NULL
by	NULL
aspecific	NULL
binding	NULL
to	NULL
the	NULL
Ni**-NTA-agarose	NULL
beads	NULL
.	NULL

of	NULL
TxA	NULL
,	NULL
or	NULL
secretion	NULL
of	NULL
ADP	NULL
,	NULL
since	NULL
inhibitors	NULL
of	NULL
both	NULL
signalling	NULL
events	NULL
,	NULL
indomethacin	NULL
and	NULL
PEP	NULL
:	NULL
PK	NULL
,	NULL
caused	NULL
only	NULL
a	NULL
slight	NULL
reduction	NULL
of	NULL
Ca**-induced	NULL
Rap1	NULL
activation	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
this	NULL
reduction	NULL
is	NULL
probably	NULL
due	NULL
to	NULL
the	NULL
slightly	NULL
lower	NULL
Ca*+*	NULL
level	NULL
induced	NULL
by	NULL
thapsigargin	NULL
and	NULL
ionomycin	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
indomethacin	NULL
and	NULL
PEP	NULL
:	NULL
PK	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
PKC	NULL
by	NULL
several	NULL
inhibitors	NULL
,	NULL
i.e	NULL
.	NULL

staurosporin	NULL
,	NULL
bisindolyImaleimid	NULL
and	NULL
calphostin	NULL
C	NULL
(	NULL
Tamaoki	NULL
,	NULL
1991	NULL
;	NULL
Toullec	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
,	NULL
did	NULL
not	NULL
at	NULL
all	NULL
or	NULL
only	NULL
marginally	NULL
affect	NULL
the	NULL
activation	NULL
of	NULL
Rapl	NULL
by	NULL
o-thrombin	NULL
(	NULL
Figure	NULL
6B	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
,	NULL
activation	NULL
of	NULL
PKC	NULL
by	NULL
the	NULL
phorbol	NULL
0	NULL
0.5	NULL
1	NULL
2	NULL
time	NULL
(	NULL
min	NULL
)	NULL
«	NULL
-	NULL
»	NULL
-|	NULL
a	NULL
Rap	NULL
+	NULL
RGDS	NULL
~-	NULL
-	NULL
-~	NULL
|	NULL
4	NULL
Rapl	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Inhibition	NULL
of	NULL
platelet	NULL
aggregation	NULL
does	NULL
not	NULL
affect	NULL
thrombin-induced	NULL
activation	NULL
of	NULL
Rap1	NULL
.	NULL

Platelets	NULL
were	NULL
treated	NULL
with	NULL
0.1	NULL
U/ml	NULL
under	NULL
aggregating	NULL
conditions	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
periods	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
+RGDS	NULL
)	NULL
or	NULL
absence	NULL
of	NULL
100	NULL
uM	NULL
of	NULL
the	NULL
aggregation-inhibitory	NULL
peptide	NULL
RGDS	NULL
added	NULL
1	NULL
min	NULL
prior	NULL
to	NULL
activation	NULL
.	NULL

Rapl	NULL
was	NULL
precipitated	NULL
with	NULL
RBD	NULL
and	NULL
analysed	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Figure	NULL
1.	NULL
ester	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
(	NULL
Kroll	NULL
and	NULL
Schafer	NULL
,	NULL
1989	NULL
;	NULL
Siess	NULL
,	NULL
1989	NULL
)	NULL
activated	NULL
Rapl	NULL
only	NULL
slightly	NULL
and	NULL
after	NULL
a	NULL
prolonged	NULL
period	NULL
of	NULL
time	NULL
(	NULL
Figure	NULL
6B	NULL
)	NULL
.	NULL

From	NULL
these	NULL
results	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
Rapl	NULL
activation	NULL
is	NULL
mediated	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
Ca**	NULL
,	NULL
which	NULL
is	NULL
both	NULL
necessary	NULL
and	NULL
sufficient	NULL
,	NULL
whereas	NULL
activation	NULL
of	NULL
PKC	NULL
does	NULL
not	NULL
play	NULL
an	NULL
essential	NULL
role	NULL
.	NULL

Prostaglandin	NULL
I	NULL
;	NULL
(	NULL
PG	NULL
I	NULL
;	NULL
)	NULL
inhibits	NULL
thrombin-	NULL
and	NULL
Ca	NULL
*	NULL
-induced	NULL
Rap1	NULL
activation	NULL
PGI	NULL
;	NULL
,	NULL
a	NULL
potent	NULL
inducer	NULL
of	NULL
cAMP	NULL
production	NULL
,	NULL
is	NULL
a	NULL
strong	NULL
antagonist	NULL
of	NULL
platelet	NULL
activation	NULL
(	NULL
Kroll	NULL
and	NULL
Schafer	NULL
,	NULL
1989	NULL
;	NULL
Siess	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
PGI	NULL
;	NULL
on	NULL
thrombin-induced	NULL
activation	NULL
of	NULL
Rapl	NULL
.	NULL

Figure	NULL
7A	NULL
shows	NULL
that	NULL
addition	NULL
of	NULL
PGI	NULL
;	NULL
inhibited	NULL
thrombin-induced	NULL
activation	NULL
of	NULL
Rapl	NULL
completely	NULL
.	NULL

Furthermore	NULL
,	NULL
when	NULL
platelets	NULL
were	NULL
first	NULL
treated	NULL
with	NULL
thrombin	NULL
and	NULL
subsequently	NULL
with	NULL
PGT	NULL
,	NULL
the	NULL
initial	NULL
activation	NULL
of	NULL
Rapl	NULL
was	NULL
followed	NULL
by	NULL
a	NULL
rapid	NULL
down-regulation	NULL
(	NULL
Figure	NULL
7B	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
Rapl	NULL
(	NULL
again	NULL
)	NULL
correlated	NULL
with	NULL
the	NULL
level	NULL
of	NULL
intracellular	NULL
Ca++	NULL
(	NULL
Figure	NULL
7C	NULL
)	NULL
.	NULL

However	NULL
,	NULL
Ca**-induced	NULL
activation	NULL
of	NULL
Rapl	NULL
by	NULL
thapsigargin	NULL
and	NULL
ionomycin	NULL
was	NULL
also	NULL
fully	NULL
blocked	NULL
by	NULL
PGI	NULL
;	NULL
(	NULL
Figure	NULL
7D	NULL
)	NULL
,	NULL
even	NULL
though	NULL
the	NULL
intracellular	NULL
Ca**	NULL
levels	NULL
induced	NULL
by	NULL
thapsigargin	NULL
or	NULL
ionomycin	NULL
were	NULL
still	NULL
high	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PGI	NULL
;	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
;	NULL
Siess	NULL
and	NULL
Lapetina	NULL
,	NULL
1989	NULL
;	NULL
Nakamura	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
Rapl	NULL
activity	NULL
is	NULL
under	NULL
tight	NULL
negative	NULL
control	NULL
of	NULL
PGI	NULL
,	NULL
which	NULL
acts	NULL
both	NULL
upstream	NULL
and	NULL
downstream	NULL
of	NULL
Ca**	NULL
.	NULL

PGI	NULL
;	NULL
activates	NULL
adenylate	NULL
cyclase	NULL
resulting	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
cAMP	NULL
level	NULL
.	NULL

It	NULL
is	NULL
intriguing	NULL
that	NULL
Rapl	NULL
is	NULL
an	NULL
in	NULL
vivo	NULL
substrate	NULL
for	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
A	NULL
(	NULL
PKA	NULL
)	NULL
(	NULL
Kawata	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Siess	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

This	NULL
phosphoryl-ation	NULL
,	NULL
which	NULL
results	NULL
in	NULL
a	NULL
lower	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
Rapl	NULL
(	NULL
Siess	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Siess	NULL
and	NULL
Grinberg	NULL
,	NULL
1993	NULL
)	NULL
,	NULL
occurs	NULL
only	NULL
slowly	NULL
and	NULL
was	NULL
still	NULL
very	NULL
limited	NULL
2	NULL
min	NULL
after	NULL
PGI	NULL
;	NULL
treatment	NULL
of	NULL
the	NULL
platelets	NULL
(	NULL
Figure	NULL
8A	NULL
;	NULL
Griinberg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

At	NULL
this	NULL
time	NULL
point	NULL
,	NULL
however	NULL
,	NULL
PGI	NULL
;	NULL
had	NULL
already	NULL
completely	NULL
inhibited	NULL
Rapl	NULL
activity	NULL
(	NULL
see	NULL
Figure	NULL
7A	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
was	NULL
able	NULL
to	NULL
activate	NULL
phosphorylated	NULL
Rapl1	NULL
apparently	NULL
normally	NULL
.	NULL

This	NULL
was	NULL
shown	NULL
by	NULL
pre-treating	NULL
platelets	NULL
with	NULL
PGI	NULL
;	NULL
for	NULL
various	NULL
times	NULL
,	NULL
followed	NULL
by	NULL
thrombin	NULL
stimulation	NULL
:	NULL
whereas	NULL
platelets	NULL
became	NULL
fully	NULL
responsive	NULL
to	NULL
thrombin	NULL
stimulation	NULL
within	NULL
60	NULL
min	NULL
after	NULL
PGI	NULL
;	NULL
addition	NULL
(	NULL
due	NULL
to	NULL
the	NULL
instability	NULL
of	NULL
PGI	NULL
)	NULL
,	NULL
Rapl	NULL
phosphorylation	NULL
remained	NULL
high	NULL
(	NULL
Figure	NULL
8A	NULL
;	NULL
Siess	NULL
and	NULL
Griinberg	NULL
,	NULL
1993	NULL
;	NULL
Rap1	NULL
activation	NULL
in	NULL
platelets	NULL
;	NULL
“	NULL
a=	NULL
as	NULL
dB	NULL
--	NULL
am	NULL
4-	NULL
Rapl	NULL
B	NULL
A	NULL
C	NULL
x	NULL
A\	NULL
.	NULL

@	NULL
4	NULL
“	NULL
(	NULL
53	NULL
(	NULL
15°	NULL
o	NULL
``	NULL
X	NULL
c	NULL
,	NULL
*	NULL
o	NULL
%	NULL
3°	NULL
®	NULL
OQQ	NULL
box	NULL
06	NULL
.	NULL

QQ	NULL
Qéy	NULL
.	NULL

9	NULL
&	NULL
4	NULL
“	NULL
\é¢	NULL
6°	NULL
_C	NULL
#	NULL
&	NULL
1	NULL
3	NULL
time	NULL
(	NULL
min	NULL
)	NULL
a	NULL
»	NULL
an	NULL
an	NULL
am	NULL
»	NULL
«	NULL
|	NULL
<	NULL
Rap	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Role	NULL
of	NULL
PLC	NULL
,	NULL
Ca**	NULL
and	NULL
PKC	NULL
in	NULL
@	NULL
-thrombin-induced	NULL
Rap1	NULL
activation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
U73122	NULL
and	NULL
BAPTA-AM	NULL
inhibit	NULL
Rapl	NULL
activation	NULL
,	NULL
whereas	NULL
ionomycin	NULL
and	NULL
thapsigargin	NULL
stimulate	NULL
it	NULL
.	NULL

Platelets	NULL
were	NULL
incubated	NULL
with	NULL
either	NULL
the	NULL
PLC	NULL
inhibitor	NULL
U73122	NULL
(	NULL
1	NULL
uM	NULL
,	NULL
3	NULL
min	NULL
)	NULL
or	NULL
the	NULL
intracellular	NULL
Ca**	NULL
chelator	NULL
BAPTA-AM	NULL
(	NULL
30	NULL
uM	NULL
,	NULL
30	NULL
min	NULL
)	NULL
prior	NULL
to	NULL
1	NULL
min	NULL
of	NULL
thrombin	NULL
(	NULL
0.1	NULL
U/ml	NULL
)	NULL
stimulation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
platelets	NULL
were	NULL
activated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
thrombin	NULL
with	NULL
either	NULL
ionomycin	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
+	NULL
CaC	NULL
]	NULL
;	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
or	NULL
thapsigargin	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
,	NULL
both	NULL
for	NULL
1	NULL
min	NULL
.	NULL

In	NULL
the	NULL
lanes	NULL
labelled	NULL
'onomycin	NULL
+	NULL
inhibitors	NULL
'	NULL
and	NULL
'thapsigargin	NULL
+	NULL
inhibitors	NULL
'	NULL
platelets	NULL
were	NULL
pre-treated	NULL
with	NULL
inhibitors	NULL
of	NULL
TxA	NULL
;	NULL
production	NULL
and	NULL
ADP	NULL
signalling	NULL
(	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Figure	NULL
2	NULL
)	NULL
prior	NULL
to	NULL
1	NULL
min	NULL
of	NULL
treatment	NULL
with	NULL
either	NULL
ionomycin	NULL
+	NULL
CaC	NULL
]	NULL
;	NULL
or	NULL
thapsigargin	NULL
.	NULL

Rapl	NULL
was	NULL
precipitated	NULL
with	NULL
RBD	NULL
and	NULL
analysed	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Figure	NULL
1	NULL
.	NULL

The	NULL
band	NULL
present	NULL
above	NULL
Rapl	NULL
on	NULL
the	NULL
blot	NULL
is	NULL
caused	NULL
by	NULL
aspecific	NULL
binding	NULL
of	NULL
protein	NULL
to	NULL
the	NULL
Ni_*-NTA-agarose	NULL
beads	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Inhibition	NULL
or	NULL
activation	NULL
of	NULL
PKC	NULL
do	NULL
not	NULL
significantly	NULL
affect	NULL
Rapl	NULL
activity	NULL
.	NULL

Platelets	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
PKC	NULL
inhibitors	NULL
staurosporin	NULL
(	NULL
1	NULL
uM	NULL
,	NULL
5	NULL
min	NULL
)	NULL
,	NULL
bisindolyImaleimid	NULL
(	NULL
5	NULL
uM	NULL
,	NULL
1	NULL
min	NULL
)	NULL
,	NULL
calphostin	NULL
C	NULL
(	NULL
5	NULL
M	NULL
,	NULL
5	NULL
min	NULL
)	NULL
prior	NULL
to	NULL
a	NULL
1	NULL
min	NULL
thrombin	NULL
stimulation	NULL
(	NULL
0.1	NULL
U/ml	NULL
!	NULL
)	NULL

(	NULL
left	NULL
panel	NULL
)	NULL
.	NULL

In	NULL
the	NULL
right	NULL
panel	NULL
,	NULL
platelets	NULL
were	NULL
stimulated	NULL
with	NULL
the	NULL
PKC-activating	NULL
phorbol	NULL
ester	NULL
PMA	NULL
(	NULL
10	NULL
nM	NULL
)	NULL
for	NULL
1	NULL
and	NULL
3	NULL
min	NULL
.	NULL

Rapl	NULL
was	NULL
precipitated	NULL
with	NULL
RBD	NULL
and	NULL
analysed	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Figure	NULL
1	NULL
.	NULL

Griinberg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
,	NULL
thrombin	NULL
activated	NULL
the	NULL
phosphorylated	NULL
,	NULL
shifted	NULL
form	NULL
of	NULL
Rap1	NULL
(	NULL
Figure	NULL
8B	NULL
)	NULL
.	NULL

We	NULL
conclude	NULL
,	NULL
therefore	NULL
,	NULL
that	NULL
the	NULL
PGI	NULL
;	NULL
-induced	NULL
inhibition	NULL
of	NULL
Rapl	NULL
activation	NULL
is	NULL
not	NULL
caused	NULL
by	NULL
phosphorylation	NULL
of	NULL
the	NULL
GTPase	NULL
.	NULL

Discussion	NULL
We	NULL
have	NULL
developed	NULL
a	NULL
novel	NULL
assay	NULL
to	NULL
identify	NULL
the	NULL
active	NULL
GTP-bound	NULL
state	NULL
of	NULL
Rapl	NULL
.	NULL

This	NULL
assay	NULL
is	NULL
based	NULL
on	NULL
the	NULL
observation	NULL
that	NULL
the	NULL
GTP-bound	NULL
form	NULL
of	NULL
Rapl	NULL
associates	NULL
255	NULL
B.Franke	NULL
,	NULL
J.-W.N.Akkerman	NULL
and	NULL
J.L.Bos	NULL
with	NULL
the	NULL
RBD	NULL
of	NULL
RalGDS	NULL
with	NULL
high	NULL
affinity	NULL
in	NULL
vitro	NULL
,	NULL
whereas	NULL
no	NULL
interaction	NULL
can	NULL
be	NULL
detected	NULL
with	NULL
the	NULL
GDP-bound	NULL
form	NULL
of	NULL
Rap1	NULL
.	NULL

When	NULL
we	NULL
incubated	NULL
cell	NULL
lysates	NULL
of	NULL
resting	NULL
and	NULL
(	NULL
-thrombin-stimulated	NULL
human	NULL
blood	NULL
platelets	NULL
A	NULL
BA	NULL
C	NULL
_-8	NULL
X	NULL
Q	NULL
&	NULL
+	NULL
&	NULL
8	NULL
``	NULL
Q0	NULL
«	NULL
&	NULL
©	NULL
aam	NULL
4	NULL
Rap	NULL
B	NULL
au	NULL
»	NULL
ap	NULL
am	NULL
»	NULL
a-	NULL
-	NULL
-	NULL
<	NULL
a	NULL
4	NULL
Rap1	NULL
15	NULL
15	NULL
15	NULL
15	NULL
15	NULL
15	NULL
15	NULL
120	NULL
0	NULL
a	NULL
«	NULL
-thrombin	NULL
(	NULL
sec	NULL
)	NULL
0	NULL
1	NULL
5	NULL
15	NULL
30	NULL
60105	NULL
0	NULL
0	NULL
PGI	NULL
;	NULL
(	NULL
sec	NULL
)	NULL
C	NULL
A	NULL
200-7	NULL
<	NULL
A	NULL
5	NULL
I	NULL
8	NULL
|	NULL
Doi	NULL
Q	NULL
,	NULL
[	NULL
o	NULL
Eo	NULL
a	NULL
J	NULL
\	NULL
&	NULL
t	NULL
100-7	NULL
i	NULL
H	NULL
‘	NULL
g	NULL
|	NULL
%	NULL
,	NULL
|	NULL
a-T	NULL
Ix	NULL
“	NULL
MY-w	NULL
«	NULL
-T	NULL
hw	NULL
}	NULL
w	NULL
a-T+PGI	NULL
;	NULL
PGi	NULL
0	NULL
``	NULL
``	NULL
|	NULL
``	NULL
``	NULL
|	NULL
``	NULL
``	NULL
|	NULL
``	NULL
'=	NULL
0	NULL
100	NULL
time	NULL
(	NULL
sec	NULL
)	NULL
it	NULL
6	NULL
``	NULL
m	NULL
03°	NULL
Qt	NULL
,	NULL
K	NULL
X	NULL
3	NULL
8:8	NULL
>	NULL
Sys	NULL
&	NULL
Cs	NULL
RRC	NULL
&	NULL
.	NULL

&	NULL
_	NULL
,	NULL
p	NULL
,	NULL
p	NULL
&	NULL
256	NULL
with	NULL
polyhistidine-tagged	NULL
RBD	NULL
bound	NULL
to	NULL
Ni°	NULL
:	NULL
*-NTA-agarose	NULL
beads	NULL
,	NULL
we	NULL
observed	NULL
a	NULL
large	NULL
amount	NULL
of	NULL
Rapl	NULL
associated	NULL
with	NULL
RBD	NULL
only	NULL
in	NULL
stimulated	NULL
platelets	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
in	NULL
vitro	NULL
binding	NULL
affinity	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
this	NULL
increase	NULL
is	NULL
due	NULL
to	NULL
an	NULL
induction	NULL
of	NULL
the	NULL
GTP-bound	NULL
form	NULL
of	NULL
Rapl	NULL
by	NULL
a-thrombin	NULL
.	NULL

Alternatively	NULL
,	NULL
Rapl	NULL
might	NULL
be	NULL
constitutively	NULL
GTP-bound	NULL
but	NULL
complexed	NULL
to	NULL
a	NULL
factor	NULL
in	NULL
resting	NULL
platelets	NULL
that	NULL
prevents	NULL
it	NULL
from	NULL
associating	NULL
with	NULL
RBD	NULL
.	NULL

Stimulation	NULL
with	NULL
thrombin	NULL
would	NULL
then	NULL
lead	NULL
to	NULL
dissociation	NULL
of	NULL
this	NULL
factor	NULL
,	NULL
rendering	NULL
Rapl	NULL
available	NULL
for	NULL
RBD	NULL
binding	NULL
.	NULL

To	NULL
discriminate	NULL
between	NULL
the	NULL
two	NULL
possi-bilities	NULL
,	NULL
the	NULL
ratio	NULL
of	NULL
GDP	NULL
and	NULL
GTP	NULL
bound	NULL
to	NULL
Rapl	NULL
in	NULL
platelets	NULL
needs	NULL
to	NULL
be	NULL
measured	NULL
.	NULL

Unfortunately	NULL
,	NULL
suitable	NULL
antisera	NULL
for	NULL
Rapl	NULL
immunoprecipitation	NULL
,	NULL
which	NULL
are	NULL
essential	NULL
for	NULL
such	NULL
an	NULL
experiment	NULL
,	NULL
are	NULL
still	NULL
not	NULL
available	NULL
.	NULL

Irrespective	NULL
of	NULL
this	NULL
,	NULL
in	NULL
functional	NULL
terms	NULL
there	NULL
may	NULL
be	NULL
no	NULL
difference	NULL
between	NULL
the	NULL
two	NULL
mechanisms	NULL
,	NULL
as	NULL
both	NULL
result	NULL
in	NULL
free	NULL
GTP-bound	NULL
,	NULL
active	NULL
Rapl	NULL
.	NULL

The	NULL
assay	NULL
was	NULL
used	NULL
to	NULL
monitor	NULL
the	NULL
activation	NULL
of	NULL
Rapl	NULL
in	NULL
platelets	NULL
.	NULL

We	NULL
observed	NULL
that	NULL
all	NULL
agonists	NULL
tested	NULL
that	NULL
activate	NULL
platelets	NULL
also	NULL
activate	NULL
Rap1	NULL
.	NULL

This	NULL
could	NULL
imply	NULL
that	NULL
Rapl	NULL
is	NULL
either	NULL
involved	NULL
in	NULL
a	NULL
signalling	NULL
pathway	NULL
common	NULL
to	NULL
all	NULL
of	NULL
these	NULL
agonists	NULL
or	NULL
that	NULL
Rapl	NULL
activation	NULL
is	NULL
a	NULL
secondary	NULL
event	NULL
,	NULL
induced	NULL
by	NULL
positive	NULL
feedback	NULL
loops	NULL
(	NULL
TxA	NULL
,	NULL
release	NULL
and	NULL
ADP	NULL
secretion	NULL
)	NULL
or	NULL
by	NULL
platelet	NULL
aggregation	NULL
,	NULL
for	NULL
instance	NULL
.	NULL

However	NULL
,	NULL
inhibition	NULL
of	NULL
both	NULL
TxA	NULL
,	NULL
production	NULL
and	NULL
ADP	NULL
signalling	NULL
as	NULL
well	NULL
as	NULL
aggregation	NULL
did	NULL
not	NULL
affect	NULL
O-thrombin-induced	NULL
activation	NULL
of	NULL
Rapl	NULL
significantly	NULL
.	NULL

This	NULL
strongly	NULL
suggests	NULL
that	NULL
Rapl	NULL
activation	NULL
is	NULL
one	NULL
of	NULL
the	NULL
early	NULL
events	NULL
in	NULL
platelet	NULL
activation	NULL
.	NULL

The	NULL
observed	NULL
translocation	NULL
of	NULL
Rapl1	NULL
to	NULL
the	NULL
cytoskeleton	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
Rap1	NULL
,	NULL
since	NULL
it	NULL
occurs	NULL
much	NULL
later	NULL
than	NULL
Rapl	NULL
activation	NULL
.	NULL

Furthermore	NULL
,	NULL
inhibition	NULL
of	NULL
actin	NULL
polymerization	NULL
by	NULL
cytochalasin	NULL
D	NULL
,	NULL
which	NULL
totally	NULL
blocked	NULL
Rapl	NULL
association	NULL
with	NULL
the	NULL
cytoskeleton	NULL
,	NULL
did	NULL
not	NULL
inhibit	NULL
Rapl	NULL
activation	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
Rapl	NULL
is	NULL
involved	NULL
in	NULL
a	NULL
signalling	NULL
pathway	NULL
common	NULL
to	NULL
all	NULL
agonists	NULL
tested	NULL
.	NULL

A	NULL
common	NULL
denominator	NULL
for	NULL
all	NULL
these	NULL
agonists	NULL
is	NULL
the	NULL
increase	NULL
in	NULL
intracellular	NULL
Ca*+*	NULL
by	NULL
mobilization	NULL
of	NULL
Ca**	NULL
from	NULL
internal	NULL
stores	NULL
and	NULL
by	NULL
influx	NULL
of	NULL
extracellular	NULL
Ca**	NULL
.	NULL

Indeed	NULL
,	NULL
we	NULL
found	NULL
that	NULL
increasing	NULL
the	NULL
concentration	NULL
of	NULL
intracellular	NULL
Ca**	NULL
with	NULL
either	NULL
ionomycin	NULL
or	NULL
thapsigargin	NULL
induced	NULL
Rapl	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

Effects	NULL
of	NULL
PGI	NULL
;	NULL
treatment	NULL
of	NULL
platelets	NULL
on	NULL
Rap1	NULL
activation	NULL
and	NULL
cytosolic	NULL
Ca*	NULL
levels	NULL
.	NULL

(	NULL
A	NULL
)	NULL
PGI	NULL
;	NULL
pre-treatment	NULL
prevents	NULL
Rapl	NULL
activation	NULL
by	NULL
o-thrombin	NULL
.	NULL

Platelets	NULL
were	NULL
treated	NULL
with	NULL
thrombin	NULL
(	NULL
0-T	NULL
,	NULL
0.1	NULL
U/ml	NULL
)	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
PGI	NULL
added	NULL
2	NULL
min	NULL
earlier	NULL
at	NULL
10	NULL
ng/ml	NULL
.	NULL

Rapl	NULL
was	NULL
precipitated	NULL
with	NULL
RBD	NULL
and	NULL
analysed	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Figure	NULL
1	NULL
.	NULL

(	NULL
B	NULL
)	NULL
PGI	NULL
;	NULL
treatment	NULL
of	NULL
o-thrombin-activated	NULL
platelets	NULL
results	NULL
in	NULL
a	NULL
time-dependent	NULL
reduction	NULL
of	NULL
Rap1	NULL
activity	NULL
.	NULL

Platelets	NULL
were	NULL
treated	NULL
with	NULL
&	NULL
-thrombin	NULL
(	NULL
0.1	NULL
U/ml	NULL
)	NULL
for	NULL
15	NULL
s	NULL
to	NULL
activate	NULL
Rap1	NULL
.	NULL

PGI	NULL
;	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

was	NULL
then	NULL
added	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
.	NULL

Controls	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
or	NULL
were	NULL
activated	NULL
with	NULL
o-thrombin	NULL
for	NULL
120	NULL
s	NULL
to	NULL
serve	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
the	NULL
activity	NULL
state	NULL
of	NULL
Rapl	NULL
at	NULL
the	NULL
end	NULL
of	NULL
the	NULL
experiment	NULL
.	NULL

Rapl	NULL
was	NULL
precipitated	NULL
with	NULL
RBD	NULL
and	NULL
analysed	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Figure	NULL
1	NULL
.	NULL

(	NULL
C	NULL
)	NULL
PGI	NULL
;	NULL
reverses	NULL
the	NULL
O-thrombin-induced	NULL
rise	NULL
in	NULL
the	NULL
cytosolic	NULL
Ca**	NULL
level	NULL
.	NULL

The	NULL
intracellular	NULL
Ca**	NULL
level	NULL
was	NULL
monitored	NULL
in	NULL
Fura-2-loaded	NULL
platelets	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL

@	NULL
-Thrombin	NULL
(	NULL
0.1	NULL
U/ml	NULL
)	NULL
was	NULL
added	NULL
at	NULL
the	NULL
indicated	NULL
time	NULL
point	NULL
(	NULL
G-T	NULL
)	NULL
,	NULL
15	NULL
s	NULL
later	NULL
PGI	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

was	NULL
added	NULL
(	NULL
indicated	NULL
with	NULL
PGI	NULL
;	NULL
)	NULL
and	NULL
incubation	NULL
was	NULL
continued	NULL
for	NULL
another	NULL
90	NULL
s.	NULL
(	NULL
D	NULL
)	NULL
PGI	NULL
;	NULL
pre-treatment	NULL
of	NULL
platelets	NULL
prevents	NULL
Rap1	NULL
activation	NULL
by	NULL
the	NULL
cytosolic	NULL
Ca**-elevating	NULL
agents	NULL
thapsigargin	NULL
and	NULL
ionomycin	NULL
.	NULL

Platelets	NULL
were	NULL
incubated	NULL
either	NULL
with	NULL
or	NULL
without	NULL
PGI	NULL
;	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
2	NULL
min	NULL
.	NULL

Subsequently	NULL
,	NULL
either	NULL
ionomycin	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
+	NULL
CaC	NULL
)	NULL
;	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
or	NULL
thapsigargin	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
was	NULL
added	NULL
for	NULL
1	NULL
min	NULL
.	NULL

Rapl	NULL
was	NULL
precipitated	NULL
with	NULL
RBD	NULL
and	NULL
analysed	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Figure	NULL
1	NULL
.	NULL

A	NULL
0	NULL
2	NULL
60	NULL
120	NULL
150	NULL
180	NULL
-	NULL
time	NULL
(	NULL
min	NULL
)	NULL
_	NULL
Rap1-P	NULL
wore	NULL
cae	NULL
,	NULL
eme	NULL
m	NULL
©	NULL
``	NULL
+=	NULL
Rap1	NULL
B	NULL
-	NULL
«	NULL
-T	NULL
+c-T	NULL
%	NULL
»	NULL
180	NULL
150	NULL
120	NULL
60	NULL
2	NULL
0	NULL
0	NULL
2	NULL
60	NULL
120	NULL
150	NULL
180	NULL
time	NULL
(	NULL
min	NULL
)	NULL
Rap1-P	NULL
Rap1	NULL
<	NULL
=	NULL
“	NULL
-——	NULL
‘	NULL
=	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

PGI	NULL
;	NULL
-induced	NULL
phosphorylation	NULL
of	NULL
Rapl	NULL
does	NULL
not	NULL
affect	NULL
Rapl	NULL
activation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
PGI	NULL
;	NULL
induces	NULL
a	NULL
mobility	NULL
shift	NULL
of	NULL
Rap1	NULL
.	NULL

Total	NULL
lysates	NULL
of	NULL
platelets	NULL
treated	NULL
with	NULL
PGI	NULL
;	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
the	NULL
indicated	NULL
time	NULL
periods	NULL
were	NULL
separated	NULL
and	NULL
analysed	NULL
by	NULL
protein	NULL
immunoblot	NULL
analysis	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
phosphorylated	NULL
Rap1	NULL
.	NULL

The	NULL
phosphorylated	NULL
form	NULL
of	NULL
Rapl	NULL
shows	NULL
decreased	NULL
electrophoretic	NULL
mobility	NULL
during	NULL
SDS-PAGE	NULL
and	NULL
can	NULL
therefore	NULL
be	NULL
detected	NULL
as	NULL
a	NULL
second	NULL
Rapl1	NULL
band	NULL
on	NULL
the	NULL
immunoblot	NULL
,	NULL
indicated	NULL
by	NULL
Rap1-P.	NULL
(	NULL
B	NULL
)	NULL
«	NULL
-Thrombin	NULL
induces	NULL
activation	NULL
of	NULL
phosphorylated	NULL
Rap1	NULL
.	NULL

Platelets	NULL
were	NULL
treated	NULL
with	NULL
PGI	NULL
;	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
the	NULL
indicated	NULL
time	NULL
periods	NULL
.	NULL

Subsequently	NULL
,	NULL
thrombin	NULL
was	NULL
added	NULL
and	NULL
the	NULL
incubation	NULL
was	NULL
continued	NULL
for	NULL
another	NULL
minute	NULL
,	NULL
followed	NULL
by	NULL
cell	NULL
lysis	NULL
(	NULL
+	NULL
«	NULL
&	NULL
-T	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
platelets	NULL
incubated	NULL
with	NULL
PGI	NULL
;	NULL
were	NULL
not	NULL
incubated	NULL
with	NULL
thrombin	NULL
Rapl	NULL
was	NULL
precipitated	NULL
with	NULL
RBD	NULL
and	NULL
analysed	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Figure	NULL
1	NULL
.	NULL

Rap1-P	NULL
indicates	NULL
the	NULL
slower	NULL
migrating	NULL
,	NULL
phosphorylated	NULL
form	NULL
of	NULL
Rap1	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
due	NULL
to	NULL
the	NULL
instability	NULL
of	NULL
PGI	NULL
;	NULL
its	NULL
inhibitory	NULL
effect	NULL
on	NULL
Rap1	NULL
activation	NULL
by	NULL
is	NULL
only	NULL
seen	NULL
2	NULL
min	NULL
after	NULL
PGI	NULL
;	NULL
addition	NULL
to	NULL
the	NULL
platelets	NULL
.	NULL

At	NULL
all	NULL
later	NULL
time	NULL
points	NULL
,	NULL
PGI	NULL
;	NULL
has	NULL
been	NULL
broken	NULL
down	NULL
and	NULL
platelets	NULL
have	NULL
restored	NULL
responsiveness	NULL
to	NULL
&	NULL
-thrombin	NULL
(	NULL
Siess	NULL
and	NULL
Lapetina	NULL
,	NULL
1990	NULL
;	NULL
Siess	NULL
and	NULL
Griinberg	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

activation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
BAPTA-AM	NULL
,	NULL
which	NULL
chelates	NULL
intracellular	NULL
Ca**	NULL
,	NULL
inhibited	NULL
thrombin-induced	NULL
Rapl	NULL
activation	NULL
.	NULL

Apparently	NULL
,	NULL
Rapl	NULL
activation	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
rise	NULL
in	NULL
intracellular	NULL
Ca**	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
the	NULL
Ca	NULL
``	NULL
+	NULL
increase	NULL
results	NULL
in	NULL
Rapl	NULL
activation	NULL
,	NULL
however	NULL
,	NULL
is	NULL
unclear	NULL
and	NULL
currently	NULL
under	NULL
investigation	NULL
.	NULL

PGI	NULL
;	NULL
,	NULL
which	NULL
activates	NULL
adenylate	NULL
cyclase	NULL
to	NULL
increase	NULL
the	NULL
levels	NULL
of	NULL
cAMP	NULL
in	NULL
platelets	NULL
,	NULL
inhibits	NULL
thrombin-induced	NULL
activation	NULL
of	NULL
Rap1	NULL
.	NULL

This	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
observation	NULL
that	NULL
PGI	NULL
;	NULL
inhibited	NULL
thrombin-induced	NULL
increases	NULL
in	NULL
intracellular	NULL
Ca**	NULL
.	NULL

However	NULL
,	NULL
thapsigargin-	NULL
or	NULL
ionomycin-induced	NULL
activation	NULL
of	NULL
Rapl	NULL
was	NULL
also	NULL
inhibited	NULL
by	NULL
PGI	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
antagonist	NULL
also	NULL
affects	NULL
a	NULL
factor	NULL
downstream	NULL
of	NULL
Ca+*	NULL
.	NULL

Although	NULL
Rapl	NULL
is	NULL
phosphorylated	NULL
after	NULL
PGI	NULL
;	NULL
treatment	NULL
of	NULL
platelets	NULL
,	NULL
it	NULL
is	NULL
unlikely	NULL
that	NULL
this	NULL
phosphorylation	NULL
causes	NULL
the	NULL
inhibition	NULL
.	NULL

We	NULL
conclude	NULL
this	NULL
from	NULL
the	NULL
observation	NULL
that	NULL
(	NULL
1	NULL
)	NULL
PGI	NULL
;	NULL
-induced	NULL
phosphorylation	NULL
of	NULL
Rapl	NULL
was	NULL
a	NULL
much	NULL
later	NULL
event	NULL
than	NULL
inhibition	NULL
of	NULL
Rap1	NULL
,	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
thrombin	NULL
could	NULL
activate	NULL
the	NULL
phosphorylated	NULL
form	NULL
of	NULL
Rapl1	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
here	NULL
that	NULL
the	NULL
detection	NULL
of	NULL
the	NULL
phosphorylated	NULL
form	NULL
of	NULL
Rapl	NULL
by	NULL
a	NULL
mobility	NULL
shift	NULL
is	NULL
an	NULL
accurate	NULL
method	NULL
,	NULL
as	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
by	NULL
others	NULL
that	NULL
PGI	NULL
;	NULL
-induced	NULL
phosphorylation	NULL
invariantly	NULL
is	NULL
accompanied	NULL
by	NULL
the	NULL
shift	NULL
in	NULL
mobility	NULL
(	NULL
Siess	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Another	NULL
Rap1	NULL
activation	NULL
in	NULL
platelets	NULL
candidate	NULL
for	NULL
mediating	NULL
the	NULL
PGI	NULL
;	NULL
inhibition	NULL
is	NULL
Rap1lGAP	NULL
.	NULL

Phosphorylation	NULL
of	NULL
this	NULL
protein	NULL
is	NULL
induced	NULL
by	NULL
elevated	NULL
levels	NULL
of	NULL
cAMP	NULL
,	NULL
at	NULL
least	NULL
in	NULL
insect	NULL
cells	NULL
and	NULL
the	NULL
SK-MEL-3	NULL
cell	NULL
line	NULL
(	NULL
Polakis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Rubinfeld	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Whether	NULL
this	NULL
occurs	NULL
in	NULL
platelets	NULL
and	NULL
whether	NULL
it	NULL
affects	NULL
GAP	NULL
activity	NULL
is	NULL
still	NULL
unknown	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
phosphorylation	NULL
of	NULL
Rap1	NULL
correlates	NULL
with	NULL
the	NULL
PGI	NULL
;	NULL
-induced	NULL
translocation	NULL
of	NULL
Rapl	NULL
from	NULL
the	NULL
plasma	NULL
membrane	NULL
to	NULL
the	NULL
cytosol	NULL
(	NULL
Lapetina	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

This	NULL
translocation	NULL
may	NULL
be	NULL
another	NULL
form	NULL
of	NULL
inactivation	NULL
by	NULL
PGI	NULL
»	NULL
,	NULL
which	NULL
clearly	NULL
interferes	NULL
at	NULL
a	NULL
different	NULL
level	NULL
of	NULL
Rap1l-mediated	NULL
signalling	NULL
.	NULL

From	NULL
the	NULL
rapid	NULL
activation	NULL
of	NULL
a	NULL
major	NULL
fraction	NULL
of	NULL
Rapl	NULL
and	NULL
the	NULL
stringent	NULL
control	NULL
of	NULL
Rapl	NULL
activity	NULL
by	NULL
PGI	NULL
»	NULL
,	NULL
we	NULL
anticipate	NULL
that	NULL
Rapl	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
agonist-induced	NULL
,	NULL
calcium-mediated	NULL
events	NULL
in	NULL
platelet	NULL
activation	NULL
.	NULL

Interestingly	NULL
,	NULL
Ca**-induced	NULL
signalling	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
integrin	NULL
oilIbB3	NULL
,	NULL
resulting	NULL
in	NULL
the	NULL
exposure	NULL
of	NULL
binding	NULL
sites	NULL
for	NULL
fibrinogen	NULL
and	NULL
,	NULL
subsequently	NULL
,	NULL
platelet	NULL
aggregation	NULL
(	NULL
Kroll	NULL
and	NULL
Schafer	NULL
,	NULL
1989	NULL
;	NULL
Siess	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

It	NULL
is	NULL
tempting	NULL
,	NULL
therefore	NULL
,	NULL
to	NULL
speculate	NULL
that	NULL
Rapl1	NULL
is	NULL
involved	NULL
in	NULL
this	NULL
process	NULL
.	NULL

Support	NULL
for	NULL
this	NULL
possibility	NULL
comes	NULL
from	NULL
the	NULL
recent	NULL
finding	NULL
that	NULL
R-ras	NULL
,	NULL
a	NULL
close	NULL
relative	NULL
of	NULL
Rapl	NULL
,	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
integrins	NULL
in	NULL
various	NULL
cell	NULL
lines	NULL
(	NULL
Zhang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

A	NULL
function	NULL
of	NULL
Rapl	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
integrins	NULL
is	NULL
not	NULL
incompatible	NULL
with	NULL
the	NULL
flat	NULL
revertant	NULL
phenotype	NULL
of	NULL
Kreyv-1/Rapl	NULL
in	NULL
transformed	NULL
fibroblasts	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Production	NULL
of	NULL
his-tagged	NULL
RalGDS-RBD	NULL
The	NULL
cDNA	NULL
encoding	NULL
the	NULL
97	NULL
amino	NULL
acids	NULL
spanning	NULL
RBD	NULL
was	NULL
isolated	NULL
from	NULL
pGEX-RGF97	NULL
(	NULL
Herrmann	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
as	NULL
a	NULL
BamHI-Xhol	NULL
fragment	NULL
.	NULL

The	NULL
BamHI	NULL
site	NULL
was	NULL
blunted	NULL
with	NULL
Klenow	NULL
DNA	NULL
polymerase	NULL
.	NULL

Subsequently	NULL
,	NULL
the	NULL
fragment	NULL
was	NULL
inserted	NULL
into	NULL
the	NULL
pET-15b	NULL
vector	NULL
(	NULL
Novagen	NULL
)	NULL
digested	NULL
with	NULL
NdeI	NULL
(	NULL
and	NULL
blunted	NULL
with	NULL
Klenow	NULL
DNA	NULL
polymerase	NULL
)	NULL
and	NULL
Xhol	NULL
.	NULL

The	NULL
construct	NULL
was	NULL
transformed	NULL
into	NULL
Escherichia	NULL
coli	NULL
(	NULL
strain	NULL
BL21	NULL
)	NULL
.	NULL

Protein	NULL
production	NULL
was	NULL
initiated	NULL
by	NULL
addition	NULL
of	NULL
isopropyl	NULL
B-p-thiogalactopyranoside	NULL
(	NULL
IPTG	NULL
)	NULL
to	NULL
the	NULL
culture	NULL
.	NULL

The	NULL
fusion	NULL
protein	NULL
was	NULL
affinity	NULL
purified	NULL
on	NULL
a	NULL
column	NULL
(	NULL
Qiagen	NULL
)	NULL
from	NULL
the	NULL
supernatant	NULL
of	NULL
bacteria	NULL
lysed	NULL
by	NULL
sonication	NULL
and	NULL
freeze-thaw	NULL
cycles	NULL
in	NULL
a	NULL
sucrose-containing	NULL
buffer	NULL
.	NULL

Isolation	NULL
and	NULL
stimulation	NULL
of	NULL
platelets	NULL
Freshly	NULL
drawn	NULL
venous	NULL
blood	NULL
from	NULL
healthy	NULL
volunteers	NULL
(	NULL
with	NULL
informed	NULL
consent	NULL
)	NULL
was	NULL
collected	NULL
into	NULL
trisodium	NULL
citrate	NULL
(	NULL
0.1	NULL
vol	NULL
.	NULL

of	NULL
130	NULL
mM	NULL
trisodium	NULL
citrate	NULL
)	NULL
.	NULL

The	NULL
donors	NULL
claimed	NULL
not	NULL
to	NULL
have	NULL
taken	NULL
any	NULL
medication	NULL
during	NULL
the	NULL
previous	NULL
10	NULL
days	NULL
.	NULL

The	NULL
blood	NULL
was	NULL
centrifuged	NULL
at	NULL
200	NULL
g	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
to	NULL
yield	NULL
platelet-rich	NULL
plasma	NULL
(	NULL
PRP	NULL
)	NULL
.	NULL

Then	NULL
,	NULL
0.1	NULL
vol	NULL
.	NULL

of	NULL
ACD	NULL
(	NULL
2.5	NULL
%	NULL
trisodium	NULL
citrate	NULL
,	NULL
1.5	NULL
%	NULL
citric	NULL
acid	NULL
,	NULL
2	NULL
%	NULL
p-glucose	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
PRP	NULL
to	NULL
lower	NULL
the	NULL
pH	NULL
of	NULL
the	NULL
plasma	NULL
to	NULL
6.5	NULL
and	NULL
thus	NULL
prevent	NULL
platelet	NULL
activation	NULL
during	NULL
further	NULL
isolation	NULL
.	NULL

Platelets	NULL
were	NULL
purified	NULL
from	NULL
PRP	NULL
by	NULL
centrifugation	NULL
at	NULL
700	NULL
g	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
platelet	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
HEPES/Tyrode	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
HEPES	NULL
,	NULL
137	NULL
mM	NULL
NaCl	NULL
,	NULL
2.68	NULL
mM	NULL
KCI	NULL
,	NULL
0.42	NULL
mM	NULL
NaH	NULL
,	NULL
PO	NULL
,	NULL
,	NULL
1.7	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
11.9	NULL
mM	NULL
NaHCO	NULL
;	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
containing	NULL
5	NULL
mM	NULL
p-glucose	NULL
at	NULL
2	NULL
X	NULL
10°	NULL
platelets/ml	NULL
.	NULL

Platelets	NULL
were	NULL
left	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
at	NULL
least	NULL
30	NULL
min	NULL
to	NULL
ensure	NULL
a	NULL
resting	NULL
state	NULL
.	NULL

Samples	NULL
of	NULL
0.5	NULL
ml	NULL
were	NULL
used	NULL
for	NULL
the	NULL
experiments	NULL
.	NULL

Purified	NULL
platelets	NULL
were	NULL
incubated	NULL
in	NULL
a	NULL
lumiaggregometer	NULL
(	NULL
CHRONO-LOG	NULL
corporation	NULL
)	NULL
at	NULL
37°C	NULL
.	NULL

In	NULL
the	NULL
standard	NULL
assay	NULL
,	NULL
incubation	NULL
with	NULL
agonists	NULL
was	NULL
without	NULL
stirring	NULL
.	NULL

Without	NULL
stirring	NULL
,	NULL
platelets	NULL
only	NULL
change	NULL
their	NULL
shape	NULL
but	NULL
do	NULL
not	NULL
aggregate	NULL
,	NULL
whereas	NULL
in	NULL
a	NULL
stirred	NULL
suspension	NULL
(	NULL
900	NULL
rp.m	NULL
.	NULL
)	NULL

platelet	NULL
shape	NULL
change	NULL
and	NULL
aggregation	NULL
occur	NULL
.	NULL

Platelet	NULL
agonists	NULL
used	NULL
in	NULL
the	NULL
study	NULL
are	NULL
:	NULL
-thrombin	NULL
which	NULL
was	NULL
added	NULL
to	NULL
the	NULL
platelets	NULL
for	NULL
1	NULL
min	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.1	NULL
,	NULL
0.2	NULL
or	NULL
0.25	NULL
U/ml	NULL
(	NULL
as	NULL
indicated	NULL
)	NULL
,	NULL
TRAP	NULL
(	NULL
6mer	NULL
:	NULL
SFLLRN	NULL
)	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
,	NULL
collagen	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
,	NULL
U46619	NULL
(	NULL
TxA	NULL
;	NULL
analogue	NULL
)	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
,	NULL
ADP	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
and	NULL
PAF	NULL
(	NULL
200	NULL
nM	NULL
)	NULL
.	NULL

PMA	NULL
was	NULL
added	NULL
to	NULL
the	NULL
platelets	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
10	NULL
nM	NULL
,	NULL
thapsigargin	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
intracellular	NULL
Ca**	NULL
ATPases	NULL
,	NULL
was	NULL
used	NULL
at	NULL
100	NULL
nM	NULL
concentration	NULL
as	NULL
was	NULL
jonomycin	NULL
,	NULL
a	NULL
Ca**	NULL
ionophore	NULL
.	NULL

In	NULL
the	NULL
257	NULL
B.Franke	NULL
,	NULL
J.-W.N.Akkerman	NULL
and	NULL
J.L.Bos	NULL
case	NULL
of	NULL
ionomycin	NULL
,	NULL
1	NULL
mM	NULL
CaCl	NULL
;	NULL
was	NULL
added	NULL
to	NULL
the	NULL
platelet	NULL
suspension	NULL
just	NULL
prior	NULL
to	NULL
stimulation	NULL
.	NULL

PGI	NULL
;	NULL
was	NULL
used	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
10	NULL
or	NULL
20	NULL
ng/ml	NULL
and	NULL
incubated	NULL
with	NULL
the	NULL
platelets	NULL
for	NULL
2	NULL
min	NULL
(	NULL
unless	NULL
indicated	NULL
otherwise	NULL
)	NULL
.	NULL

The	NULL
PLC	NULL
inhibitor	NULL
U73122	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
was	NULL
present	NULL
during	NULL
3	NULL
min	NULL
pre-incubation	NULL
.	NULL

The	NULL
inactive	NULL
component	NULL
U73343	NULL
used	NULL
as	NULL
control	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
Rapl	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

BAPTA-AM	NULL
(	NULL
30	NULL
M	NULL
)	NULL
,	NULL
an	NULL
intracellular	NULL
Ca**	NULL
chelator	NULL
,	NULL
was	NULL
pre-incubated	NULL
with	NULL
the	NULL
platelet	NULL
suspension	NULL
for	NULL
30	NULL
min	NULL
.	NULL

Indomethacin	NULL
(	NULL
30	NULL
uM	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
platelets	NULL
for	NULL
10	NULL
min	NULL
to	NULL
inhibit	NULL
TxA	NULL
;	NULL
formation	NULL
.	NULL

The	NULL
ADP	NULL
scavenger	NULL
PEP	NULL
:	NULL
PK	NULL
was	NULL
freshly	NULL
prepared	NULL
prior	NULL
to	NULL
every	NULL
experiment	NULL
and	NULL
added	NULL
to	NULL
the	NULL
platelets	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.28	NULL
mM	NULL
PEP	NULL
and	NULL
3	NULL
U/	NULL
ml	NULL
PK	NULL
1	NULL
min	NULL
before	NULL
stimulation	NULL
.	NULL

PKC	NULL
inhibitors	NULL
were	NULL
used	NULL
as	NULL
follows	NULL
:	NULL
staurosporin	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
,	NULL
5	NULL
min	NULL
incubation	NULL
,	NULL
bisindolylmaleimid	NULL
(	NULL
5	NULL
uM	NULL
)	NULL
,	NULL
1	NULL
min	NULL
incubation	NULL
,	NULL
calphostin	NULL
C	NULL
(	NULL
5	NULL
M	NULL
)	NULL
,	NULL
5	NULL
min	NULL
incubation	NULL
.	NULL

Cytochalasin	NULL
D	NULL
was	NULL
added	NULL
to	NULL
the	NULL
platelet	NULL
suspension	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
5	NULL
ug/	NULL
ml	NULL
5	NULL
min	NULL
prior	NULL
to	NULL
platelet	NULL
stimulation	NULL
.	NULL

The	NULL
peptide	NULL
RGDS	NULL
was	NULL
used	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
100	NULL
uM	NULL
and	NULL
was	NULL
added	NULL
to	NULL
the	NULL
platelets	NULL
1	NULL
min	NULL
prior	NULL
to	NULL
stimulation	NULL
.	NULL

RGDS	NULL
binds	NULL
to	NULL
the	NULL
ligand	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
platelet	NULL
integrin	NULL
olIbB3	NULL
.	NULL

It	NULL
inhibits	NULL
binding	NULL
of	NULL
fibrinogen	NULL
to	NULL
the	NULL
integrin	NULL
and	NULL
therefore	NULL
blocks	NULL
platelet	NULL
aggregation	NULL
.	NULL

RGDS	NULL
does	NULL
not	NULL
activate	NULL
outside-in	NULL
signalling	NULL
of	NULL
integrin	NULL
allbB3	NULL
(	NULL
Hynes	NULL
,	NULL
1992	NULL
;	NULL
Calvete	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

Rap1	NULL
activation	NULL
assay	NULL
using	NULL
RalGDS-RBD	NULL
Platelets	NULL
were	NULL
lysed	NULL
by	NULL
addition	NULL
of	NULL
1	NULL
vol	NULL
.	NULL

of	NULL
cold	NULL
2X	NULL
RIPA	NULL
lysis	NULL
buffer	NULL
[	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
100	NULL
mM	NULL
Tris-HCl	NULL
pH	NULL
7.4	NULL
,	NULL
2	NULL
%	NULL
NP-40	NULL
,	NULL
1	NULL
%	NULL
deoxycholic	NULL
acid	NULL
(	NULL
DOC	NULL
)	NULL
,	NULL
0.2	NULL
%	NULL
SDS	NULL
,	NULL
2	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
2	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
(	NULL
PMSF	NULL
)	NULL
,	NULL
2	NULL
uM	NULL
leupeptin	NULL
,	NULL
2	NULL
M	NULL
aprotinin	NULL
]	NULL
to	NULL
the	NULL
platelet	NULL
suspension	NULL
.	NULL

Lysis	NULL
was	NULL
performed	NULL
at	NULL
4°C	NULL
for	NULL
10-30	NULL
min	NULL
.	NULL

Lysates	NULL
were	NULL
clarified	NULL
by	NULL
centrifugation	NULL
at	NULL
maximal	NULL
speed	NULL
in	NULL
an	NULL
Eppendorf	NULL
centrifuge	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Five	NULL
ug	NULL
of	NULL
RalGDS-RBD	NULL
coupled	NULL
to	NULL
Ni°*-NTA-agarose	NULL
beads	NULL
(	NULL
Qiagen	NULL
)	NULL
were	NULL
added	NULL
to	NULL
the	NULL
supernatant	NULL
and	NULL
incubated	NULL
at	NULL
4°C	NULL
for	NULL
30-90	NULL
min	NULL
with	NULL
slight	NULL
agitation	NULL
.	NULL

Beads	NULL
were	NULL
washed	NULL
four	NULL
times	NULL
in	NULL
1X	NULL
RIPA	NULL
.	NULL

After	NULL
the	NULL
final	NULL
wash	NULL
,	NULL
Laemmli	NULL
sample	NULL
buffer	NULL
was	NULL
added	NULL
to	NULL
the	NULL
samples	NULL
.	NULL

Next	NULL
,	NULL
proteins	NULL
were	NULL
fractionated	NULL
by	NULL
SDS-PAGE	NULL
and	NULL
transferred	NULL
to	NULL
polyvi-nylidene	NULL
difluoride	NULL
membranes	NULL
(	NULL
Immobilon-P	NULL
,	NULL
Millipore	NULL
)	NULL
.	NULL

The	NULL
antibody	NULL
used	NULL
specifically	NULL
to	NULL
detect	NULL
Rapl	NULL
was	NULL
a	NULL
monoclonal	NULL
antibody	NULL
directed	NULL
against	NULL
Rapl	NULL
(	NULL
Transduction	NULL
Laboratories	NULL
)	NULL
.	NULL

Immune	NULL
complexes	NULL
were	NULL
detected	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

All	NULL
experiments	NULL
shown	NULL
here	NULL
were	NULL
performed	NULL
at	NULL
least	NULL
three	NULL
times	NULL
with	NULL
the	NULL
same	NULL
result	NULL
to	NULL
exclude	NULL
donor-specific	NULL
effects	NULL
.	NULL

Calcium	NULL
measurements	NULL
PRP	NULL
was	NULL
prepared	NULL
as	NULL
described	NULL
above	NULL
.	NULL

ACD	NULL
was	NULL
added	NULL
and	NULL
platelets	NULL
were	NULL
incubated	NULL
with	NULL
3	NULL
1M	NULL
Fura-2-AM	NULL
for	NULL
45	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

Surplus	NULL
Fura-2-AM	NULL
and	NULL
plasma	NULL
were	NULL
removed	NULL
by	NULL
gel	NULL
filtration	NULL
over	NULL
a	NULL
Sepharose	NULL
2B	NULL
column	NULL
equilibrated	NULL
in	NULL
HEPES/Tyrode	NULL
buffer	NULL
.	NULL

Measurement	NULL
of	NULL
the	NULL
cytosolic	NULL
Ca**	NULL
concentration	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
Hitachi	NULL
F4500	NULL
fluorescence	NULL
spectrophotometer	NULL
by	NULL
a	NULL
dual	NULL
wavelength	NULL
program	NULL
(	NULL
excitation	NULL
was	NULL
measured	NULL
at	NULL
340	NULL
nm	NULL
and	NULL
380	NULL
nm	NULL
,	NULL
emission	NULL
at	NULL
510	NULL
nm	NULL
)	NULL
.	NULL

Cell	NULL
fractionation	NULL
Samples	NULL
of	NULL
5X10°	NULL
platelets/ml	NULL
were	NULL
lysed	NULL
in	NULL
cold	NULL
2X	NULL
CSK	NULL
buffer	NULL
(	NULL
100	NULL
mM	NULL
Tris-HCI	NULL
,	NULL
20	NULL
mM	NULL
EGTA	NULL
,	NULL
2	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
2	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
2	NULL
mM	NULL
PMSF	NULL
,	NULL
2	NULL
pg/ml	NULL
aprotinin	NULL
,	NULL
2	NULL
jig/ml	NULL
leupeptin	NULL
)	NULL
after	NULL
stimulation	NULL
.	NULL

Lysis	NULL
was	NULL
for	NULL
at	NULL
least	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Lysates	NULL
were	NULL
centrifuged	NULL
at	NULL
maximal	NULL
speed	NULL
in	NULL
an	NULL
Eppendorf	NULL
centrifuge	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
pellet	NULL
containing	NULL
the	NULL
actin	NULL
cytoskeleton	NULL
of	NULL
the	NULL
lysed	NULL
platelets	NULL
was	NULL
washed	NULL
once	NULL
with	NULL
1X	NULL
CSK	NULL
buffer	NULL
and	NULL
centrifuged	NULL
as	NULL
before	NULL
.	NULL

Laemmli	NULL
sample	NULL
buffer	NULL
was	NULL
added	NULL
to	NULL
the	NULL
pellet	NULL
.	NULL

Amounts	NULL
of	NULL
protein	NULL
representing	NULL
equal	NULL
numbers	NULL
of	NULL
platelets	NULL
were	NULL
used	NULL
for	NULL
SDS-PAGE	NULL
.	NULL

Acknowledgements	NULL
We	NULL
thank	NULL
Fred	NULL
Wittinghofer	NULL
for	NULL
communicating	NULL
the	NULL
high	NULL
affinity	NULL
of	NULL
RBD	NULL
for	NULL
Rapl	NULL
prior	NULL
to	NULL
publication	NULL
,	NULL
Marcel	NULL
Spaargaren	NULL
for	NULL
the	NULL
RBD	NULL
construct	NULL
and	NULL
our	NULL
colleagues	NULL
for	NULL
support	NULL
,	NULL
discussions	NULL
and	NULL
critically	NULL
reading	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
grant	NULL
provided	NULL
by	NULL
the	NULL
Netherlands	NULL
Heart	NULL
Foundation	NULL
(	NULL
grant	NULL
94.136	NULL
)	NULL
.	NULL

References	NULL
Altschuler	NULL
,	NULL
D.L	NULL
.	NULL

,	NULL
Peterson	NULL
,	NULL
S.N	NULL
.	NULL

,	NULL
Ostrowski	NULL
,	NULL
M.C	NULL
.	NULL

and	NULL
Lapetina	NULL
,	NULL
F.G	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Cyclic	NULL
AMP-dependent	NULL
activation	NULL
of	NULL
Raplb	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
BioL	NULL
,	NULL
270	NULL
,	NULL
10373-10376	NULL
.	NULL

258	NULL
Ammit	NULL
,	NULL
A.J	NULL
.	NULL

and	NULL
O'Neill	NULL
,	NULL
C	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Rapid	NULL
and	NULL
selective	NULL
measurement	NULL
of	NULL
platelet-activating	NULL
factor	NULL
using	NULL
a	NULL
quantitative	NULL
bioassay	NULL
of	NULL
platelet	NULL
aggregation	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

Methods	NULL
,	NULL
26	NULL
,	NULL
7-21	NULL
.	NULL

Authi	NULL
,	NULL
K.S	NULL
.	NULL

,	NULL
Bokkola	NULL
,	NULL
S.	NULL
,	NULL
Patel	NULL
,	NULL
Y.	NULL
,	NULL
Kakkar	NULL
,	NULL
V.V	NULL
.	NULL

and	NULL
Munkonge	NULL
,	NULL
F	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Ca®*	NULL
release	NULL
from	NULL
platelet	NULL
intracellular	NULL
stores	NULL
by	NULL
thapsigargin	NULL
and	NULL
2,5-di-	NULL
(	NULL
¢-butyl	NULL
)	NULL
-1,4-benzohydroquinone	NULL
:	NULL
relationship	NULL
to	NULL
Ca**	NULL
pools	NULL
and	NULL
relevance	NULL
in	NULL
platelet	NULL
activation	NULL
.	NULL

Biochem	NULL
.	NULL

J.	NULL
,	NULL
294	NULL
,	NULL
119-126	NULL
.	NULL

Benton	NULL
,	NULL
A.M.	NULL
,	NULL
Gerrard	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
Michiel	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Kindon	NULL
,	NULL
S.E	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
Are	NULL
lysophosphatidic	NULL
acids	NULL
or	NULL
phosphatic	NULL
acids	NULL
involved	NULL
in	NULL
stimulus	NULL
activation	NULL
coupling	NULL
in	NULL
platelets	NULL
?	NULL

Blood	NULL
,	NULL
60	NULL
,	NULL
642-649	NULL
.	NULL

Burgering	NULL
,	NULL
B.M.T	NULL
.	NULL

,	NULL
Pronk	NULL
,	NULL
G.J	NULL
.	NULL

,	NULL
van	NULL
Weeren	NULL
,	NULL
P.C	NULL
.	NULL

,	NULL
Chardin	NULL
,	NULL
P	NULL
.	NULL

and	NULL
Bos	NULL
,	NULL
J.L	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
cAMP	NULL
antagonizes	NULL
p21	NULL
``	NULL
``	NULL
-directed	NULL
activation	NULL
of	NULL
extracellular	NULL
signal-regulated	NULL
kinase	NULL
2	NULL
and	NULL
phosphorylation	NULL
of	NULL
mSOS	NULL
nucleotide	NULL
exchange	NULL
factor	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
12	NULL
,	NULL
4211-4220	NULL
.	NULL

Calvete	NULL
,	NULL
J.J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Clues	NULL
for	NULL
understanding	NULL
the	NULL
structure	NULL
and	NULL
function	NULL
of	NULL
a	NULL
prototypic	NULL
human	NULL
integrin	NULL
:	NULL
the	NULL
platelet	NULL
glycoprotein	NULL
complex	NULL
.	NULL

Thromb	NULL
.	NULL

Haemostasis	NULL
,	NULL
72	NULL
,	NULL
1-15	NULL
.	NULL

Campa	NULL
,	NULL
M.J.	NULL
,	NULL
Chang	NULL
,	NULL
K.J	NULL
.	NULL

,	NULL
Molina	NULL
y	NULL
Vedia	NULL
,	NULL
L.	NULL
,	NULL
Reep	NULL
,	NULL
B.R	NULL
.	NULL

and	NULL
Lapetina	NULL
,	NULL
E.G	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Inhibition	NULL
of	NULL
Ras-induced	NULL
germinal	NULL
vesicle	NULL
breakdown	NULL
in	NULL
Xenopus	NULL
oocytes	NULL
by	NULL
Rap-1B	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
174	NULL
,	NULL
1-5	NULL
.	NULL

Cavallini	NULL
,	NULL
L	NULL
.	NULL

and	NULL
Alexandre	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Calcium	NULL
efflux	NULL
from	NULL
platelets	NULL
.	NULL

Eur	NULL
:	NULL
J	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
222	NULL
,	NULL
693-702	NULL
.	NULL

Cavallini	NULL
,	NULL
L.	NULL
,	NULL
Coassin	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Alexandre	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Two	NULL
classes	NULL
of	NULL
agonist-sensitive	NULL
Ca**	NULL
stores	NULL
in	NULL
platelets	NULL
,	NULL
as	NULL
identified	NULL
by	NULL
their	NULL
differential	NULL
sensitivity	NULL
__	NULL
to	NULL
_	NULL
2,5-di-	NULL
(	NULL
¢ert-butyl	NULL
)	NULL
-1,4-benzohydroquinone	NULL
_	NULL
and	NULL
thapsigargin	NULL
.	NULL

Biochem	NULL
.	NULL

J.	NULL
,	NULL
310	NULL
,	NULL
449-452	NULL
.	NULL

Cook	NULL
,	NULL
S.J	NULL
.	NULL

and	NULL
McCormick	NULL
,	NULL
F	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Inhibition	NULL
by	NULL
cAMP	NULL
of	NULL
Ras-dependent	NULL
activation	NULL
of	NULL
Raf	NULL
.	NULL

Science	NULL
,	NULL
262	NULL
,	NULL
1069-1072	NULL
.	NULL

Cook	NULL
,	NULL
S.	NULL
,	NULL
Rubinfeld	NULL
,	NULL
B.	NULL
,	NULL
Albert	NULL
,	NULL
I	NULL
and	NULL
McCormick	NULL
,	NULL
F	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
RapV12	NULL
antagonizes	NULL
Ras-dependent	NULL
activation	NULL
of	NULL
ERK1	NULL
and	NULL
ERK2	NULL
by	NULL
LPA	NULL
and	NULL
EGF	NULL
in	NULL
Rat-1	NULL
fibroblasts	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
12	NULL
,	NULL
3475-3485	NULL
.	NULL

Dash	NULL
,	NULL
D.	NULL
,	NULL
Aepfelbacher	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Siess	NULL
,	NULL
W.	NULL
(	NULL
1995	NULL
)	NULL
Integrin	NULL
oIbB3-mediated	NULL
translocation	NULL
of	NULL
CDC42Hs	NULL
to	NULL
the	NULL
cytoskeleton	NULL
in	NULL
stimulated	NULL
human	NULL
platelets	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
270	NULL
,	NULL
17321-17326	NULL
.	NULL

Doni	NULL
,	NULL
M.G	NULL
.	NULL

,	NULL
Cavallini	NULL
,	NULL
L	NULL
.	NULL

and	NULL
Alexandre	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Ca**	NULL
influx	NULL
in	NULL
platelets	NULL
:	NULL
activation	NULL
by	NULL
thrombin	NULL
and	NULL
by	NULL
the	NULL
depletion	NULL
of	NULL
the	NULL
stores	NULL
.	NULL

Effect	NULL
of	NULL
cyclic	NULL
nucleotides	NULL
.	NULL

Biochem	NULL
.	NULL

J.	NULL
,	NULL
303	NULL
,	NULL
599-605	NULL
.	NULL

Fischer	NULL
,	NULL
T.H	NULL
.	NULL

,	NULL
Gatling	NULL
,	NULL
M.N	NULL
.	NULL

,	NULL
Lacal	NULL
,	NULL
J.-C.	NULL
and	NULL
White	NULL
,	NULL
G.C	NULL
.	NULL

,	NULL
II	NULL
(	NULL
1990	NULL
)	NULL
Rap1B	NULL
,	NULL
a	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
substrate	NULL
,	NULL
associates	NULL
with	NULL
the	NULL
platelet	NULL
cytoskeleton	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
265	NULL
,	NULL
19405-19408	NULL
.	NULL

Fischer	NULL
,	NULL
T.H	NULL
.	NULL

,	NULL
Gatling	NULL
,	NULL
M.N	NULL
.	NULL

,	NULL
McCormick	NULL
,	NULL
E	NULL
,	NULL
Duffy	NULL
,	NULL
C.M	NULL
.	NULL

and	NULL
White	NULL
,	NULL
G.C	NULL
.	NULL

,	NULL
II	NULL
(	NULL
1994	NULL
)	NULL
Incorporation	NULL
of	NULL
Raplb	NULL
into	NULL
the	NULL
platelet	NULL
cytoskeleton	NULL
is	NULL
dependent	NULL
on	NULL
thrombin	NULL
activation	NULL
and	NULL
extracellular	NULL
calcium	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
269	NULL
,	NULL
17257-17261	NULL
.	NULL

Fox	NULL
,	NULL
J.E.B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
The	NULL
platelet	NULL
cytoskeleton	NULL
.	NULL

Thromb	NULL
.	NULL

Haemostasis	NULL
,	NULL
70	NULL
,	NULL
884-893	NULL
.	NULL

Frech	NULL
,	NULL
M.	NULL
,	NULL
John	NULL
,	NULL
J.	NULL
,	NULL
Pizon	NULL
,	NULL
V.	NULL
,	NULL
Chardin	NULL
,	NULL
P	NULL
,	NULL
Tavitian	NULL
,	NULL
A.	NULL
,	NULL
Clark	NULL
,	NULL
R.	NULL
,	NULL
McCormick	NULL
,	NULL
F	NULL
.	NULL

and	NULL
Wittinghofer	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Inhibition	NULL
of	NULL
GTPase	NULL
activating	NULL
protein	NULL
stimulation	NULL
of	NULL
ras-p21	NULL
GTPase	NULL
by	NULL
the	NULL
Krev-1	NULL
gene	NULL
product	NULL
.	NULL

Science	NULL
,	NULL
249	NULL
,	NULL
169-171	NULL
.	NULL

Gabig	NULL
,	NULL
T.G	NULL
.	NULL

,	NULL
Crean	NULL
,	NULL
C.D	NULL
.	NULL

,	NULL
Mantel	NULL
,	NULL
PL	NULL
.	NULL

and	NULL
Rosli	NULL
,	NULL
R	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Function	NULL
of	NULL
wild-type	NULL
or	NULL
mutant	NULL
RacZ	NULL
and	NULL
Rapla	NULL
GTPases	NULL
in	NULL
differentiated	NULL
HL6O	NULL
cell	NULL
NADPH	NULL
oxidase	NULL
activation	NULL
.	NULL

Blood	NULL
,	NULL
85	NULL
,	NULL
804-811	NULL
.	NULL

Griinberg	NULL
,	NULL
B.	NULL
,	NULL
Kruse	NULL
,	NULL
H.-J	NULL
.	NULL

,	NULL
Negrescu	NULL
,	NULL
E.V	NULL
.	NULL

and	NULL
Siess	NULL
,	NULL
W	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Platelet	NULL
Rap1B	NULL
phosphorylation	NULL
is	NULL
a	NULL
sensitive	NULL
marker	NULL
for	NULL
the	NULL
action	NULL
of	NULL
cyclic	NULL
AMP-	NULL
and	NULL
cyclic	NULL
GMP-increasing	NULL
platelet	NULL
inhibitors	NULL
and	NULL
vasodilators	NULL
.	NULL

J.	NULL
Cardiovasc	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
25	NULL
,	NULL
545-551	NULL
.	NULL

Hartwig	NULL
,	NULL
(	NULL
1992	NULL
)	NULL
Mechanisms	NULL
of	NULL
actin	NULL
rearrangements	NULL
mediating	NULL
platelet	NULL
activation	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

,	NULL
118	NULL
,	NULL
1421-1442	NULL
.	NULL

Hata	NULL
,	NULL
Y.	NULL
,	NULL
Kikuchi	NULL
,	NULL
A.	NULL
,	NULL
Sasaki	NULL
,	NULL
T.	NULL
,	NULL
Schaber	NULL
,	NULL
M.D	NULL
.	NULL

,	NULL
Gibbs	NULL
,	NULL
J.B	NULL
.	NULL

and	NULL
Takai	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Inhibition	NULL
of	NULL
the	NULL
ras	NULL
p21	NULL
GTPase-activating	NULL
protein-stimulated	NULL
GTPase	NULL
activity	NULL
of	NULL
c-Ha-ras	NULL
p21	NULL
by	NULL
smg	NULL
p21	NULL
having	NULL
the	NULL
same	NULL
putative	NULL
effector	NULL
domain	NULL
as	NULL
ras	NULL
p21s	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

,	NULL
265	NULL
,	NULL
7104-7107	NULL
.	NULL

Herrmann	NULL
,	NULL
C.	NULL
,	NULL
Hom	NULL
,	NULL
G.	NULL
,	NULL
Spaargaren	NULL
,	NULL
.M	NULL
.	NULL

and	NULL
Wittinghofer	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Differential	NULL
interaction	NULL
of	NULL
the	NULL
Ras	NULL
family	NULL
GTP-binding	NULL
proteins	NULL
H-Ras	NULL
,	NULL
Rap1A	NULL
,	NULL
and	NULL
R-Ras	NULL
with	NULL
the	NULL
putative	NULL
effector	NULL
molecules	NULL
Raf	NULL
kinase	NULL
and	NULL
Ral-guanine	NULL
nucleotide	NULL
exchange	NULL
factor	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
271	NULL
,	NULL
6794-6800	NULL
.	NULL

Hynes	NULL
,	NULL
R.O	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Integrins	NULL
:	NULL
versality	NULL
,	NULL
modulation	NULL
,	NULL
and	NULL
signaling	NULL
in	NULL
cell	NULL
adhesion	NULL
.	NULL

Cell	NULL
,	NULL
69	NULL
,	NULL
11-25	NULL
.	NULL

Inazu	NULL
,	NULL
T.	NULL
,	NULL
Taniguchi	NULL
,	NULL
T.	NULL
,	NULL
Ohta	NULL
,	NULL
S.	NULL
,	NULL
Miyabo	NULL
,	NULL
S	NULL
.	NULL

and	NULL
Yamamura	NULL
,	NULL
H	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
The	NULL
lectin	NULL
wheat	NULL
germ	NULL
agglutinin	NULL
induces	NULL
rapid	NULL
protein-tyrosine	NULL
phosphorylation	NULL
in	NULL
human	NULL
platelets	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
174	NULL
,	NULL
1154-1158	NULL
.	NULL

Kawata	NULL
,	NULL
M.	NULL
,	NULL
Kikuchi	NULL
,	NULL
A.	NULL
,	NULL
Hoshijima	NULL
,	NULL
M.	NULL
,	NULL
Yamamoto	NULL
,	NULL
K.	NULL
,	NULL
Hashimoto	NULL
,	NULL
E.	NULL
,	NULL
Yamamura	NULL
,	NULL
H	NULL
.	NULL

and	NULL
Takai	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Phosphorylation	NULL
of	NULL
smg	NULL
p21	NULL
,	NULL
a	NULL
ras	NULL
p2l-like	NULL
GTP-binding	NULL
protein	NULL
,	NULL
by	NULL
cyclic	NULL
AMP-dependent	NULL
protein	NULL
kinase	NULL
in	NULL
a	NULL
cell-free	NULL
system	NULL
and	NULL
in	NULL
response	NULL
to	NULL
prostaglandin	NULL
E	NULL
;	NULL
in	NULL
intact	NULL
human	NULL
platelets	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
264	NULL
,	NULL
15688-15695	NULL
.	NULL

Kroll	NULL
,	NULL
and	NULL
Schafer	NULL
,	NULL
A.I	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Biochemical	NULL
mechanisms	NULL
of	NULL
platelet	NULL
activation	NULL
.	NULL

Blood	NULL
,	NULL
74	NULL
,	NULL
1181-1195	NULL
.	NULL

Lapetina	NULL
,	NULL
B.G	NULL
.	NULL

,	NULL
Lacal	NULL
,	NULL
J.C.	NULL
,	NULL
Reep	NULL
,	NULL
B.R	NULL
.	NULL

and	NULL
Molina	NULL
y	NULL
Vedia	NULL
,	NULL
L	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
A	NULL
ras-related	NULL
protein	NULL
is	NULL
phosphorylated	NULL
and	NULL
translocated	NULL
by	NULL
agonists	NULL
that	NULL
increase	NULL
cAMP	NULL
levels	NULL
in	NULL
human	NULL
platelets	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
86	NULL
,	NULL
3131-3134	NULL
.	NULL

Nakamura	NULL
,	NULL
K.	NULL
,	NULL
Kimura	NULL
,	NULL
M.	NULL
and	NULL
Aviv	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Role	NULL
of	NULL
cyclic	NULL
nucleotides	NULL
in	NULL
store-mediated	NULL
external	NULL
Ca®*	NULL
entry	NULL
in	NULL
human	NULL
platelets	NULL
.	NULL

Biochem	NULL
.	NULL

J.	NULL
,	NULL
310	NULL
,	NULL
263-269	NULL
.	NULL

Nassar	NULL
,	NULL
N.	NULL
,	NULL
Hom	NULL
,	NULL
G.	NULL
,	NULL
Hermann	NULL
,	NULL
C.	NULL
,	NULL
Scherer.A	NULL
.	NULL

,	NULL
McCormick	NULL
,	NULL
F	NULL
.	NULL

and	NULL
Wittinghofer	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
The	NULL
2.2	NULL
A	NULL
crystal	NULL
structure	NULL
of	NULL
the	NULL
Ras-binding	NULL
domain	NULL
of	NULL
the	NULL
serine/threonine	NULL
kinase	NULL
c-Rafl	NULL
in	NULL
complex	NULL
with	NULL
Rap1A	NULL
and	NULL
a	NULL
GTP-analogue	NULL
.	NULL

Nature	NULL
,	NULL
375	NULL
,	NULL
554-560	NULL
.	NULL

Noda	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Structures	NULL
and	NULL
functions	NULL
of	NULL
the	NULL
Krev-1	NULL
transformation	NULL
suppressor	NULL
gene	NULL
and	NULL
its	NULL
relatives	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
,	NULL
1155	NULL
,	NULL
97-109	NULL
.	NULL

Okamoto	NULL
,	NULL
Y.	NULL
,	NULL
Ninomiya	NULL
,	NULL
N.	NULL
,	NULL
Miwa	NULL
,	NULL
S	NULL
.	NULL

and	NULL
Masaki	NULL
,	NULL
T	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Capacitative	NULL
entry	NULL
in	NULL
human	NULL
platelets	NULL
is	NULL
resistant	NULL
to	NULL
nitric	NULL
oxide	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
212	NULL
,	NULL
90-96	NULL
.	NULL

Polakis	NULL
,	NULL
P.	NULL
,	NULL
Rubinfeld	NULL
,	NULL
B	NULL
.	NULL

and	NULL
McCormick	NULL
,	NULL
F	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Phosphorylation	NULL
of	NULL
raplGAP	NULL
in	NULL
vivo	NULL
and	NULL
by	NULL
cAMP-dependent	NULL
kinase	NULL
and	NULL
the	NULL
cell	NULL
cycle	NULL
p34	NULL
kinase	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
267	NULL
,	NULL
10780-10785	NULL
.	NULL

Quinn	NULL
,	NULL
M.	NULL
,	NULL
Parkos	NULL
,	NULL
C.A	NULL
.	NULL

,	NULL
Walker	NULL
,	NULL
L.	NULL
,	NULL
Orkin	NULL
,	NULL
S.H	NULL
.	NULL

,	NULL
Dinauer	NULL
,	NULL
M.C	NULL
.	NULL

and	NULL
Jesaitis	NULL
,	NULL
A.J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Association	NULL
of	NULL
a	NULL
Ras-related	NULL
protein	NULL
with	NULL
cytochrome	NULL
&	NULL
of	NULL
human	NULL
neutrophils	NULL
,	NULL
Nature	NULL
,	NULL
342	NULL
,	NULL
198-200	NULL
.	NULL

Rubinfeld	NULL
,	NULL
B.	NULL
,	NULL
Crosier	NULL
,	NULL
W.J	NULL
.	NULL

,	NULL
Albert	NULL
,	NULL
I.	NULL
,	NULL
Conroy	NULL
,	NULL
L.	NULL
,	NULL
Clark	NULL
,	NULL
R.	NULL
,	NULL
McCormick	NULL
,	NULL
F	NULL
.	NULL

and	NULL
Polakis	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Localization	NULL
of	NULL
the	NULL
rap1GAP	NULL
catalytic	NULL
domain	NULL
and	NULL
sites	NULL
of	NULL
phosphorylation	NULL
by	NULL
mutational	NULL
analysis	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
12	NULL
,	NULL
4634-4642	NULL
.	NULL

Shen	NULL
,	NULL
T.Y	NULL
.	NULL

and	NULL
Winter	NULL
,	NULL
C.A	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
Chemical	NULL
and	NULL
biological	NULL
studies	NULL
on	NULL
indomethacin	NULL
,	NULL
sulindac	NULL
and	NULL
their	NULL
analogs	NULL
.	NULL

Adv	NULL
.	NULL

Drug	NULL
Res	NULL
.	NULL

,	NULL
12	NULL
,	NULL
89-245	NULL
.	NULL

Siess	NULL
,	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
Molecular	NULL
mechanisms	NULL
of	NULL
platelet	NULL
activation	NULL
.	NULL

Physiol	NULL
.	NULL

Rev	NULL
.	NULL

,	NULL
69	NULL
,	NULL
58-178	NULL
.	NULL

Siess	NULL
,	NULL
W.	NULL
and	NULL
Griinberg	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Phosphorylation	NULL
of	NULL
rap1B	NULL
by	NULL
protein	NULL
kinase	NULL
A	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
platelet	NULL
inhibition	NULL
by	NULL
cyclic	NULL
AMP	NULL
.	NULL

Cell	NULL
Signal	NULL
.	NULL

,	NULL
5	NULL
,	NULL
209-214	NULL
.	NULL

Siess	NULL
,	NULL
W.	NULL
and	NULL
Lapetina	NULL
,	NULL
E.G	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Prostacyclin	NULL
inhibits	NULL
platelet	NULL
aggregation	NULL
induced	NULL
by	NULL
phorbol	NULL
ester	NULL
or	NULL
a	NULL
Ca**	NULL
ionophore	NULL
at	NULL
steps	NULL
distal	NULL
to	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
and	NULL
Ca**-dependent	NULL
protein	NULL
kinases	NULL
.	NULL

Biochem	NULL
.	NULL

J.	NULL
,	NULL
258	NULL
,	NULL
57-65	NULL
.	NULL

Siess	NULL
,	NULL
W.	NULL
,	NULL
Winegar	NULL
,	NULL
D.A	NULL
.	NULL

and	NULL
Lapetina	NULL
,	NULL
E.G	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Rapl-B	NULL
is	NULL
phosphorylated	NULL
by	NULL
protein	NULL
kinase	NULL
A	NULL
in	NULL
intact	NULL
human	NULL
platelets	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
170	NULL
,	NULL
944-950	NULL
.	NULL

Spaargaren	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Bischoff	NULL
,	NULL
J.R	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Identification	NULL
of	NULL
the	NULL
guanine	NULL
nucleotide	NULL
dissociation	NULL
stimulator	NULL
for	NULL
Ral	NULL
as	NULL
a	NULL
putative	NULL
effector	NULL
molecule	NULL
of	NULL
R-ras	NULL
,	NULL
H-ras	NULL
,	NULL
K-ras	NULL
,	NULL
and	NULL
Rap	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
91	NULL
,	NULL
12609-12613	NULL
.	NULL

Tamaoki	NULL
,	NULL
T	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Use	NULL
and	NULL
specificity	NULL
of	NULL
staurosporine	NULL
,	NULL
UCN-01	NULL
,	NULL
and	NULL
calphostin	NULL
C	NULL
as	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

,	NULL
201	NULL
,	NULL
340-347	NULL
.	NULL

Torti	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Lapetina	NULL
,	NULL
E.G	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Role	NULL
of	NULL
Rap1B	NULL
and	NULL
p21	NULL
``	NULL
*	NULL
GTPase-activating	NULL
protein	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
phospholipase	NULL
C-yl	NULL
in	NULL
human	NULL
platelets	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
89	NULL
,	NULL
7796-7800	NULL
.	NULL

Torti	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Lapetina	NULL
,	NULL
E.G	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Structure	NULL
and	NULL
function	NULL
of	NULL
rap	NULL
proteins	NULL
in	NULL
human	NULL
platelets	NULL
.	NULL

Thromb	NULL
.	NULL

Haemostasis	NULL
,	NULL
71	NULL
,	NULL
533-543	NULL
.	NULL

Toullec	NULL
,	NULL
D	NULL
.	NULL

et	NULL
al	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
The	NULL
bisindolyImaleimide	NULL
GF	NULL
109203X	NULL
is	NULL
a	NULL
potent	NULL
and	NULL
selective	NULL
inhibitor	NULL
of	NULL
protein	NULL
kinase	NULL
C.	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
266	NULL
,	NULL
15771-15781	NULL
.	NULL

Van	NULL
Willigen	NULL
,	NULL
G.	NULL
,	NULL
Hers	NULL
,	NULL
L	NULL
,	NULL
Corter	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Akkerman	NULL
,	NULL
J.-W.N	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Exposure	NULL
of	NULL
ligand-binding	NULL
sites	NULL
on	NULL
platelet	NULL
integrin	NULL
a	NULL
I4/B	NULL
;	NULL
,	NULL
by	NULL
phosphorylation	NULL
of	NULL
the	NULL
B	NULL
;	NULL
subunit	NULL
.	NULL

Biochem	NULL
.	NULL

J.	NULL
,	NULL
314	NULL
,	NULL
769-779	NULL
.	NULL

Watson	NULL
,	NULL
S.P	NULL
.	NULL

,	NULL
Poole	NULL
,	NULL
A	NULL
.	NULL

and	NULL
Asselin	NULL
,	NULL
)	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Ethylene	NULL
glycol	NULL
bis	NULL
(	NULL
B-aminoethyl	NULL
ether	NULL
)	NULL
-N	NULL
'	NULL
,	NULL
V	NULL
'	NULL
,	NULL
NV	NULL
'	NULL
,	NULL
NV	NULL
'	NULL
-tetraacetic	NULL
acid	NULL
(	NULL
EGTA	NULL
)	NULL
and	NULL
the	NULL
tyrphostin	NULL
S	NULL
$	NULL
T271	NULL
inhibit	NULL
phospholipase	NULL
C	NULL
in	NULL
human	NULL
platelets	NULL
by	NULL
preventing	NULL
Ca**	NULL
entry	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
47	NULL
,	NULL
823-830	NULL
.	NULL

Wittinghofer	NULL
,	NULL
A	NULL
.	NULL

and	NULL
Herrmann	NULL
,	NULL
C	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Ras-effector	NULL
interactions	NULL
,	NULL
the	NULL
problem	NULL
of	NULL
specificity	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

,	NULL
369	NULL
,	NULL
52-56	NULL
.	NULL

Wu	NULL
,	NULL
J.	NULL
,	NULL
Dent	NULL
,	NULL
P.	NULL
,	NULL
Jelinek	NULL
,	NULL
T.	NULL
,	NULL
Wolfman	NULL
,	NULL
A.	NULL
,	NULL
Weber	NULL
,	NULL
M.J	NULL
.	NULL

and	NULL
Sturgill	NULL
,	NULL
(	NULL
1993	NULL
)	NULL
Inhibition	NULL
of	NULL
the	NULL
EGF-activated	NULL
Map	NULL
kinase	NULL
signal	NULL
pathway	NULL
by	NULL
adenosine	NULL
3',5'-monophosphate	NULL
.	NULL

Science	NULL
,	NULL
262	NULL
,	NULL
1065-1069	NULL
.	NULL

Yoshida	NULL
,	NULL
Y.	NULL
,	NULL
Kawata	NULL
,	NULL
M.	NULL
,	NULL
Miura	NULL
,	NULL
Y.	NULL
,	NULL
Musha	NULL
,	NULL
T.	NULL
,	NULL
Sasaki	NULL
,	NULL
T.	NULL
,	NULL
Kikuchi	NULL
,	NULL
A	NULL
.	NULL

and	NULL
Takai	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Microinjection	NULL
of	NULL
smg/rapI/Krev-1	NULL
p21	NULL
into	NULL
Swiss	NULL
3T3	NULL
cells	NULL
induces	NULL
DNA	NULL
synthesis	NULL
and	NULL
morphological	NULL
changes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
12	NULL
,	NULL
3407-3414	NULL
.	NULL

Rap1	NULL
activation	NULL
in	NULL
platelets	NULL
Zhang	NULL
,	NULL
Z.	NULL
,	NULL
Vuori	NULL
,	NULL
K.	NULL
,	NULL
Wang	NULL
,	NULL
H.-G.	NULL
,	NULL
Reed	NULL
,	NULL
J.C	NULL
.	NULL

and	NULL
Ruoslahti	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Integrin	NULL
activation	NULL
by	NULL
R-ras	NULL
.	NULL

Cell	NULL
,	NULL
85	NULL
,	NULL
61-69	NULL
.	NULL

Received	NULL
on	NULL
September	NULL
13	NULL
,	NULL
1996	NULL
259	NULL

